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Prostate cancer is a heterogeneous disease affecting an increasing number of men all 
over the world, but particularly in the countries with the Western lifestyle. The best 
biomarker assay currently available for the diagnosis of the disease, the measurement 
of prostate specific antigen (PSA) levels from blood, lacks specificity, and even when 
combined with invasive tests such as digital rectal exam and prostate tissue biopsies, 
these methods can both miss cancers, and lead to overdiagnosis and subsequent 
overtreatment of cancers. Moreover, they cannot provide an accurate prognosis for the 
disease. Due to the high prevalence of indolent prostate cancers, the majority of men 
affected by prostate cancer would be able to live without any medical intervention. 
Their latent prostate tumors would not cause any clinical symptoms during their 
lifetime, but few are willing to take the risk, as currently there are no methods or 
biomarkers to reliably differentiate the indolent cancers from the aggressive, lethal 
cases that really are in need of immediate medical treatment. 
This doctoral work concentrated on validating 12 novel candidate genes for use as 
biomarkers for prostate cancer by measuring their mRNA expression levels in prostate 
tissue and peripheral blood of men with cancer as well as unaffected individuals. The 
panel of genes included the most prominent markers in the current literature: PCA3 and 
the fusion gene TMPRSS2-ERG, in addition to BMP-6, FGF-8b, MSMB, PSCA, 
SPINK1, and TRPM8; and the kallikrein-related peptidase genes 2, 3, 4, and 15. Truly 
quantitative reverse-transcription PCR assays were developed for each of the genes for 
the purpose, time-resolved fluorometry was applied in the real-time detection of the 
amplification products, and the gene expression data were normalized by using 
artificial internal RNA standards. 
Cancer-related, statistically significant differences in gene transcript levels were found 
for TMPRSS2-ERG, PCA3, and in a more modest scale, for KLK15, PSCA, and 
SPINK1. PCA3 RNA was found in the blood of men with metastatic prostate cancer, 
but not in localized cases of cancer, suggesting limitations for using this method for 
early cancer detection in blood. TMPRSS2-ERG mRNA transcripts were found more 
frequently in cancerous than in benign prostate tissues, but they were present also in 
51% of the histologically benign prostate tissues of men with prostate cancer, while 
being absent in specimens from men without any signs of prostate cancer. PCA3 was 
shown to be 5.8 times overexpressed in cancerous tissue, but similarly to the fusion 
gene mRNA, its levels were upregulated also in the histologically benign regions of the 
tissue if the corresponding prostate was harboring carcinoma. These results indicate a 
possibility to utilize these molecular assays to assist in prostate cancer risk evaluation 









Eturauhassyöpä on heterogeeninen tauti, joka koskettaa kasvavaa määrää miehiä 
ympäri maailman, mutta erityisesti länsimaista elämäntyyliä edustavissa maissa. 
Eturauhassyöpädiagnostiikan tarpeisiin paras tällä hetkellä tarjolla oleva 
biomerkkiainemääritys, prostataspesifisen antigeenin (PSA) pitoisuuden määritys 
verestä, ei ole tarpeeksi spesifinen käyttötarkoitukseensa. Vaikka kyseiseen testiin 
yhdistetään peräsuolen kautta tehtävä eturauhasen tunnustelu ja eturauhasesta otettujen 
koepalojen tutkiminen kudostutkimustasolla, voi osa syövistä jäädä diagnosoimatta. 
Toisaalta niitä voidaan diagnosoida tarpeettomasti, mikä voi johtaa myös 
ylihoitamiseen. Mainitut diagnoosimenetelmät eivät myöskään pysty ennustamaan 
taudinkehitystä. Koska suuri osa eturauhassyövistä on hitaasti kasvavia ja kliinisesti 
merkityksettömiä, suurin osa miehistä, joilla syöpä todetaan, pystyisi elämään latentin 
kasvaimen kanssa ilman lääketieteellistä hoitoakin koko elinaikansa, ilman että kasvain 
ehtii aiheuttaa kliinisiä oireita missään vaiheessa. Harvat potilaat kuitenkaan valitsevat 
tätä vaihtoehtoa, koska käytössä ei ole menetelmiä tai biomerkkiaineita, joilla voitaisiin 
luotettavasti todeta, mitkä syövät kuuluvat hitaasti etenevään alaluokkaan, ja mitkä taas 
ovat aggressiivisia ja välitöntä lääketieteellistä hoitoa vaativia syöpiä. 
Tässä väitöskirjatyössä tutkittiin kahdentoista uuden biomerkkiaineeksi ehdotetun 
geenin soveltuvuutta eturauhassyöpädiagnostiikkaan. Niiden lähetti-RNA-tasoja 
mitattiin sekä eturauhassyöpää sairastavien että terveiden henkilöiden 
eturauhaskudoksessa ja veressä. Tutkittuihin geeneihin kuuluivat alan kirjallisuudessa 
tällä hetkellä näkyvimmin esiintyvät merkkiaineet PCA3-geeni ja fuusiogeeni 
TMPRSS2-ERG, sekä BMP-6-, FGF-8b-, KLK2-, KLK3-, KLK4-, KLK15-, MSMB-, 
PSCA-, SPINK1- ja TRPM8-geenit. Kunkin geenin ilmenemistason mittaamiseen 
kehitettiin absoluuttisesti kvantitatiivinen käänteiskopiointi-PCR-määritys, jossa 
monistustuotteet havaittiin reaaliaikaisesti aikaerotteisen fluorometrian avulla, ja 
tulokset normalisoitiin keinotekoisen, sisäisen standardi-RNA:n avulla. 
Viiden tutkitun geenin – TMPRSS2-ERG:n, PCA3:n, KLK15:n, PSCA:n ja SPINK1:n – 
ilmenemistasoissa havaittiin tilastollisesti merkitseviä, syöpään viittaavia muutoksia. 
PCA3-RNA:ta löydettiin verestä vain jo-levinneiden syöpien tapauksissa, mikä 
rajoittanee menetelmän käyttöä syövän varhaiseen havaitsemiseen verestä. TMPRSS2-
ERG-lähetti-RNA:ta löydettiin useammin eturauhaskudoksesta, jos kyseessä oli 
syöpäkudos, mutta myös 51 prosentista niitä histologisesti hyvänlaatuisia kudoksia, 
jotka olivat peräisin syöpää sisältävistä eturauhasista. Tätä merkkiainetta ei kuitenkaan 
havaittu miehillä, joilla ei ollut todettu merkkejä eturauhassyövästä. PCA3-geenin 
osoitettiin yli-ilmenevän 5.8-kertaisesti syöpäkudoksessa, mutta sen ilmeneminen oli 
lisääntynyt syöpäisissä eturauhasissa myös histologisesti hyvänlaatuisilla 
kudosalueilla. Tulokset antavat aiheen olettaa, että molekyylitason määrityksiä 
voitaisiin mahdollisesti käyttää eturauhassyöpäriskin arvioinnissa erityisesti, jos 








Prostate cancer is an increasingly common disease affecting men in all parts of the 
world. At an estimate, 1.1 million men were diagnosed with it worldwide in 2012, with 
a corresponding mortality rate of 307 000 (International Agency for Research on 
Cancer, 2012). These numbers deem it the second most common cancer in men after 
lung cancer, and the fifth leading cause of cancer-related death, accounting for 6.6% of 
the cancer-related deaths in men. However, mortality rates are decreasing due to the 
advances in cancer care and diagnostics, and not all prostate cancers are lethal by 
nature. Taken together, these indicate that most of the men affected by prostate cancer 
die rather with it than of it, and those with the indolent or slowly growing subtype 
could benefit more from watchful waiting management than from aggressive cancer 
treatments that come with the price of side effects reducing the quality of life. Yet the 
cases that would lead to death should be caught as early as possible, before they reach 
the metastatic or hormone-resistant stages at which the available treatments are only 
palliative. Differentiation between these two categories of disease course is, however, 
challenging with the current methods. 
Presently, the diagnosis of prostate cancer is performed on the basis of increased 
prostate specific antigen (PSA) levels in serum and abnormal results in digital rectal 
examination (DRE) of the prostate, and confirmed by needle biopsies of the prostate 
tissue. The first biomarker for prostate cancer, PSA protein, was suggested for use in 
prostate cancer diagnostics in 1980 (Papsidero et al., 1980) and its measurement from 
serum by immunoassays has since become a routine diagnostic tool. Despite its 
shortcomings, it is still the best available biomarker option for routine diagnostics of 
prostate cancer (Sartori & Chan 2014). The drawbacks in the sensitivity and specificity 
of the PSA test are that the serum PSA levels are often – but not always – elevated in 
cancer, and conversely, an increase in the leakage of PSA to serum can also be caused 
by benign conditions of the prostate. This can lead to unnecessary biopsies, and yet, the 
biopsy process itself can leave cancers undetected if the sampling procedure misses the 
carcinoma foci.  
In addition to proteins, nucleic acids can serve as cancer biomarkers. In fact, during the 
last decade, the research efforts have resulted in reports on two novel candidate genes 
with high prostate cancer-specificity: PCA3 (Bussemakers et al., 1999) and TMPRSS2-
ERG (Tomlins et al., 2005). The success of PCA3 has already been translated into a 
commercial urine-based test for the detection of prostate cancers with improved 
specificity (Groskopf et al., 2006). Research on these and other novel biomarkers 
described in the medical literature is still ongoing, but if validated, they could 
potentially and conceivably be used for the early detection, prognosis, and/or 
monitoring of the cancer in a noninvasive manner in blood or urine, or they could 
complement the information obtained by histological examination of the biopsy tissue 







biomarker alone will be able to replace PSA, and instead, a combination of several 
markers should be used for optimal results. The ideal combination has not been found 
yet, and therefore studies on the cancer-related changes in the expression of the 
candidate genes are highly important forming the basis for the development of the new 









2 LITERATURE REVIEW 
2.1 Prostate cancer 
2.1.1 Prostate and its diseases 
Prostate is a male secretory gland often described as being acorn-shaped and walnut-
sized. It is located below the urinary bladder, and the urethra runs through the prostate 
between the bladder and the penis. The main function of the prostate is to produce fluid 
components for seminal fluid. During ejaculation, sperm from testes and fluid from 
seminal vesicles are transported through the prostate via ejaculatory ducts and mixed 
with the prostate-produced secretion. The alkaline seminal fluid mixture is 
subsequently expelled from the body through the urethra.  
The prostate gland can be divided into three zones – transitional, central and peripheral 
zone – as suggested by McNeal (1968). The transitional zone surrounds the urethra 
closest to the bladder, the ejaculatory ducts run through the central zone, and the 
peripheral zone, containing the majority of the glandular tissue, is situated closest to 
the rectum. The prostate consists of muscle cells controlling the movement of the 
urethra, glandular cells producing the secretions, and fibrous cells forming the 
supportive structure of the organ. Normal prostate ductal system consists of three 
epithelial cell types: luminal secretory cells producing the secretory proteins; basal 
cells located between the luminal cells and the basement membrane; and, as the most 
sparse population, neuroendocrine cells supporting the growth of the luminal cells 
(Abate-Shen & Shen 2000). 
Diseases of the prostate include inflammation, benign prostatic hyperplasia (BPH) and 
prostate cancer. BPH, the benign enlargement of the prostate resulting in urinary 
problems, is predominantly found in the transitional zone of the prostate (McNeal 
1978), whereas cancers most frequently develop in the peripheral zone. Peripheral zone 
tumors can be palpated by a urologist through the rectum, but occult cancers that 
originate in the central zone can be too far inside to be reached by the DRE procedure. 
2.1.2 Risk factors 
The origin of prostate cancer is unknown, but several either nonmodifiable or 
behavioral risk factors have been reported. As reviewed by Leitzmann & Rohrmann 
(2012), the predetermined factors include age, ethnic origin, and a familial history of 
prostate cancer. In his review, Grönberg (2003) has stated that 40% of prostate cancers 
have a genetic component, and according to recent data, up to 25% of the familial 
causes of prostate cancer can be explained by the susceptibility loci in the genome 







Prostate cancer is predominantly seen in older men. It is diagnosed most often in men 
over the age of 70 with a notable increase in incidence compared to men under the age 
of 50 (Leitzmann & Rohrmann 2012). Fewer than 0.1% of the patients fall into the 
latter category (Grönberg 2003). 
The incidence of prostate cancer varies depending on ethnic origin. The African-
American population has been found to have a higher rate of prostate cancer than 
Caucasian-American men (Taksler et al., 2012). Lowest incidence rates are seen in 
China, Japan and India (Boyle et al., 1995). However, there is evidence that Asian men 
that do develop prostate cancer may be genetically predisposed to a more aggressive 
subtype (Lichtensztajn et al., 2014). An increased rate has been observed in men of 
Japanese descent after they have immigrated to the United States, which supports the 
hypothesis that lifestyle factors, i.e. dietary and other behavioral habits, may have an 
effect on the development of the disease (Haenszel 1961). 
Overall data on the dietary risk factors of prostate cancer are inconclusive, but in some 
studies a diet rich in meat or dairy products has been found to play a role in increasing 
the risk, whereas the consumption of tomatoes, soy, or cruciferous vegetables such as 
cabbage or broccoli would be beneficial in preventing cancer formation. Lycopene 
found in tomatoes is believed to protect DNA from free radicals and thereby prevent 
DNA damage in cells (Leitzmann & Rohrmann 2012). Isothiocyanates in cruciferous 
vegetables have been suggested to prevent cancers due to their ability to induce 
enzymes responsible for carcinogen detoxification (Joseph et al., 2004). 
2.1.3 Carcinogenesis 
Prostate cancer is heterogeneous and multifocal by nature. Upon histological 
examination, the tissue can contain several distinct malignant tumor foci and 
precancerous lesions known as prostatic intraepithelial neoplasia (PIN). PIN can be 
classified as low-grade PIN or high-grade PIN which is considered as a precursor of 
the carcinoma. The precursor lesions are seen also in younger men, but not all will 
develop into clinical tumors. The development of a microscopic lesion into a clinical 
tumor will often take years or decades (Leitzmann & Rohrmann 2012).  
In the early stages, the carcinoma is confined to the prostatic capsule. Most of these 
cancers are still indolent, and will not develop into a clinical disease during the lifetime 
of the individual. However, without clinical intervention, the prostate cancers prone to 
be more aggressive will later advance by invading the seminal vesicles, metastasizing 
with preference to the bone, and subsequently shifting to an androgen-independent 
stage that is now referred to as castration-resistant prostate cancer (CRPC). This results 
from the androgen-deprivation therapy commonly used for treatment of prostate 
cancer, and five different mechanisms of development are described in the review by 
Feldman & Feldman (2001). In the hypersensitive pathway, even reduced androgen 







receptor, increased conversion of testosterone to the more potent androgen, 
dihydrotestosterone, or gene amplification leading to higher amounts of the receptor 
itself. The stem cell hypothesis comprises the theory that a small population of 
epithelial stem cells that are already able to bypass the androgen regulation exists from 
the beginning, and depriving the cells of androgen facilitates the selective growth of 
those cell populations in the tumor. Mutations in the androgen receptor can lead to 
promiscuous activation of the receptor by antagonists such as flutamide or 
corticosteroids. In the bypass pathway the cell is stimulated to proliferate by unrelated 
pathways, and in the outlaw pathway the receptor is phosphorylated by other kinases 
instead of using androgen as the ligand (Feldman & Feldman 2001). De novo androgen 
synthesis in the tumor can drive the growth as well (Locke et al., 2008). The metastatic 
and hormone-resistant stages resulting from these developments are predominantly 
lethal (Abate-Shen & Shen 2000). 
Prostate cancer, like all cancers, is ultimately caused by a series of subsequent 
molecular alterations that disrupt the control of cell cycle and/or apoptosis and lead to 
uncontrolled growth and proliferation of the cells. As reviewed by Mazaris and 
Tsiotras (2013), molecular events suggested to contribute to prostate carcinogenesis 
include inactivation of tumor suppressor genes such as Rb, TP53, or PTEN, or 
activation of oncogenes such as the gene coding for androgen receptor, leading to 
abnormally active, sensitive, or specific androgen signaling and thereby proliferation of 
prostate cells. Epigenetic changes such as mutations in genes affecting chromatin 
modifications can also play a role in inappropriate activation or inactivation of genes in 
prostate cancer (Barbieri et al., 2013). In general, altered cell-cycle control is thought 
to be the primary cause of the cancer progression at the localized stage, whereas 
deregulated apoptosis accounts for the growth at the further advanced phase of the 
cancer (Abate-Shen & Shen 2000).  
2.1.4 Cancer management 
When the prostate carcinoma is still confined within the capsule, the cancers are 
essentially curable. Treatment costs are also lower for the early-stage disease than for 
the advanced forms. The age and general health of the patient, the clinical stage of the 
cancer, and the histological grade play a role in treatment decisions (Catalona 1994). 
The clinical stage describes the extent of the cancer. The so-called TNM classification 
reports the extent of the primary tumor (T), the status of spreading to lymph nodes (N), 
and the presence of metastases (M). The detailed classification system is presented in 
Table 1.  
The most commonly used system for histological grading is the scale originally 
presented by Donald Gleason in 1974 (Gleason & Mellinger 1974). In the Gleason 
system, the tissue to be graded falls into one of five histological patterns (Gleason 







representing the most differentiated and 5 the least differentiated cell type. Gleason 
score is determined by adding together the two most predominant grades present in the 
tumor, thereby resulting in a number on a scale from 2 to 10. 
Table 1. Tumor-Node-Metastasis classification of prostate cancer. Adapted from Catalona 
(1994) and American Joint Committee on Cancer (2014). 
Category to be assessed Stage  Definition 
Primary tumor TX  Primary tumor cannot be assessed 
 T0  No evidence of tumor 
 T1  Tumor clinically unapparent, not palpable or visible by 
imaging 
  T1a Incidental histological finding in 5% or less of the 
resected tissue 
  T1b Incidental histological finding in more than 5% of the 
resected tissue 
  T1c Identified by needle biopsy but not palpable or visible 
by imaging 
 T2  Tumor confined within the prostate 
  T2a Involves half a lobe or less 
  T2b Involves more than half a lobe but not both lobes 
  T2c Involves both lobes 
 T3  Tumor extends through the prostate capsule 
  T3a Extends unilaterally or bilaterally 
  T3b Invades seminal vesicles 
 T4  Tumor fixed or invades adjacent structures other than 
seminal vesicles 
Regional lymph nodes NX  Lymph nodes cannot be assessed 
 N0  No evidence of spread to lymph nodes 
 N1  Metastasis in regional lymph nodes 
Distant metastasis MX  Metastases cannot be assessed 
 M0  No distant metastases 
 M1  Distant metastases 
  M1a Metastases in nonregional lymph nodes 
  M1b Metastases in bone 








The management options for prostate cancer include active surveillance, curative 
treatment, and palliative care. Clinically localized disease is managed by active 
surveillance, if the patient has T1a cancer and a life expectancy of less than 10 years, 
and radical prostatectomy or radiation therapy at other T1 and T2 stages. Surgical 
removals of the prostate have fewer complications if performed at the early stages. 
Radiation therapy is chosen especially for those men who are older, and in poorer 
general health with clinically advanced disease and tumors of higher grade. Cancers 
that are locally advanced to stage T3, i.e., extended through the prostate capsule, are 
also treated with surgery or radiation therapy, but these may not be able to cure the 
disease as many men with T3 tumors also have occult metastases. Fewer than 15% of 
the cancers that have metastasized to lymph nodes are curable with any of the 
treatment modalities. The options, however, include hormonal therapy in addition to 
the previously mentioned surgery and radiation therapy. As the growth of prostate 
tumors is androgen-dependent, hormonal therapy will slow disease progression, but 
will not cure the cancer. The mechanisms of the hormonal therapy include suppressing 
gonadotropin secretion, and thereby testosterone secretion, by agonists, and blocking 
the binding of androgens to their receptors, among others. The symptoms of cancers 
that have spread beyond the lymph nodes can be palliated with hormonal therapy 
(Catalona 1994). However, the androgen-ablation therapy results in the recurrence of 
highly aggressive metastatic cancer that has escaped androgen control, as has been 
described in Chapter 2.1.3. Patients with the hormone-resistant cancer can be 
administered secondary hormonal treatments or palliative radiation therapy in order to 
diminish the size of the metastases, but the results are poor and temporary, and patients 
will relapse (Catalona 1994). 
2.1.5 Diagnosis 
The most prominent side effects of the treatments of prostate cancer include blood loss, 
impotence, and urinary incontinence (Catalona 1994). As mentioned in Chapter 2.1.3, 
most prostate cancers are of the indolent type, and active surveillance would suffice 
and be preferential for their management because, in these cases, the benefits achieved 
by the treatments may not outweigh the side effects. Therefore, in order to avoid the 
overtreatment of the clinically insignificant cancers, the ongoing challenge for the 
diagnostics is not only to detect the cancers early, but also to identify the men suffering 
from the aggressive form that requires robust intervention and treatment.  
In the United States, the incidence of prostate cancer showed a sharp increase in the 
early 1990s (Tiwari & Roy 2012). However, the mortality rates have been fairly stable 
since the 1970s. The sudden increase in the incidence was largely due to improved 
diagnostics, as shown by the introduction of the PSA test. The current routine 
diagnostics involve the initial suspicion of cancer after elevated serum PSA levels and 
abnormal DRE results. The suspicions are confirmed or rejected by the histological 
examination of core needle tissue biopsies taken from the prostate through the rectum 







despite being the best-performing biomarker at the moment, PSA does not provide the 
sensitivity or specificity (Table 2) required for optimal diagnosis and prognosis. 
Elevated PSA levels can be associated with benign hyperplastic conditions (Catalona 
1994), and conversely, almost a quarter of prostate cancer patients can present serum 
PSA levels lower than the often recommended cut-off of 4 ng/mL (Catalona et al., 
1997). The biopsy procedure usually consists of the examination of 6–12 biopsy cores, 
but it can still miss cancers, and it has been shown that simply increasing the number 
of tissue cores taken does not improve the detection rate (Andriole 2009, 
Delongchamps et al., 2009). In addition to missing cancers, undergrading and 
understaging of tumors based on biopsies is an issue that can lead to incorrect 
treatment choices. Underestimations can occur due to preoperative clinical factors such 
as serum PSA level, or when the prostate is large or the tumor volume is not 
appropriately presented in the biopsies. New biomarkers to either replace or work in 
collaboration with PSA are therefore urgently needed – not only to aid in diagnosing 
the malignancy, but, ideally, also to provide more specific information on the 
prognosis. 
Table 2. Diagnostic measures: sensitivity and specificity. 
 Disease present Disease absent 
Test positive True positives False positives 
Test negative False negatives True negatives 
   
 Sensitivity: Specificity: 
 True positives 
True positives + False negatives 
True negatives 
True negatives + False positives 
 
2.2 Finding biomarkers for prostate cancer: challenges in gene 
expression experiments 
Research on gene expression is one of the keys to both understanding the biology of 
cancer, and finding suitable molecules to be used as diagnostic and prognostic 
biomarkers of the disease. Differential gene expression in malignant conditions can be 
caused by changes in the genome, such as variability in copy numbers of the genes or 
rearrangements of the genetic material. In addition, epigenetic changes can also 
regulate the expression, as well as specific clearing of mRNAs before they are used for 
protein translation. Studying the cell mRNA content facilitates the identification of the 
genes expressed, as well as the extent thereof, at the time of the sample collection. 







identification of the genes that are important to the formation of the malignant state or, 
alternately, the recognition of the genes the expression of which is affected by the 
malignancy. Gene transcripts falling into either category could subsequently be used as 
biomarkers. 
As molecules highly susceptible to degradation, mRNAs are a challenging group of 
analytes to detect: sensitive, state-of-the-art methods for sample collection, processing, 
and analysis are called for, but standardized protocols for these are yet to be achieved. 
This doctoral work concentrated on differentially expressed mRNAs in prostate tissue 
and this chapter of the literature review provides a background for the technological 
aspects of this type of gene expression research and discusses the most prevalent 
challenges in the experimental settings. 
2.2.1 Specimen collection  
Prostate cancer originates in prostate tissue, and therefore the basic understanding of 
gene expression alterations in neoplastic conditions starts at tissue level research. 
Prostate tissue material can be collected from preoperative biopsies, prostate chips 
produced by a transurethral resection of the prostate (TURP), prostatectomy 
specimens, autopsy specimens or cystoprostatectomy specimens. For molecular 
research, it would be important to know the exact morphology of the original tissue 
under study, but often this information is impossible to obtain. As is discussed in more 
detail in Chapter 2.2.2, the fixation of the tissue for histological examinations renders 
the cells inapplicable for mRNA measurements. Therefore, the surrounding adjacent 
tissue usually has to serve as a surrogate for the estimation of the content of the sample 
intended for molecular assays. In addition to cancerous tissue of different stages and 
grades, controls are invaluable for research set-ups. BPH tissue is often used as a 
control for noncancerous tissue but, as benign hyperplasia is most prevalent in the 
transitional zone of the prostate, whereas cancer more often develops in the peripheral 
zone (McNeal 1968), this may create a liability for comparisons, as genes have been 
found to present zone-specific expression (van der Heul-Nieuwenhuijsen et al., 2006). 
Histologically benign tissues can be collected from cancerous prostates, but recent 
reports on molecular changes observed also in the regions surrounding malignant 
tumors (Nonn et al., 2009) could conceivably diminish their value as control tissue, 
when differences between healthy and cancerous states are examined. Yet, due to the 
invasive nature of tissue collection, obtaining prostate tissue from healthy men without 
any prostatic diseases is challenging. Autopsy tissue from organ donors (Chan et al., 
1999), or prostate tissue from cystoprostatectomy specimens performed on bladder 
cancer patients can be an alternative source of noncancerous tissue. However, as 
prostate cancer is highly prevalent in the population, especially in the aging subgroup 
of men, microscopic tumor foci can be found even in men without clinical symptoms 
and, therefore, careful pathological evaluation of the prostates obtained from organ 
donors or bladder cancer patients should be performed to ensure that the prostates are 







issue with organ donation specimens due to the fact that they are usually obtained from 
fairly young individuals. 
Going towards improved diagnostics and monitoring of prostate cancer, less invasive 
settings would be preferable, and the use of bodily fluids such as peripheral blood and 
urine has been investigated. In addition to measurements with the more traditional 
protein assays, blood can be examined for circulating tumor cells or free circulating 
nucleic acids. In some types of leukemia, the detection of tumor-specific transcripts in 
blood to monitor the disease is already in routine clinical use (Zhen & Wang 2013). 
However, the high background count of millions of lymphocytes per circulating tumor 
cell can pose a problem in epithelial cancers such as the prostate cancer, and highly 
sensitive detection methods are therefore called for. Furthermore, the enrichment of 
tumor cells is usually required for improved sensitivity, and it can be performed by 
immunoaffinity techniques or other methods that specifically capture the circulating 
tumor cells based on their physical properties (Alix-Panabieres & Pantel 2013). 
Urine has been proven to contain not only prostatic cells, shed from the prostate 
particularly in cancer cases, and after the manipulation of the prostate through prostatic 
massage or digital rectal examination; but also exosomes, vesicles of prostatic origin 
that can contain tissue-specific proteins; and nucleic acids. Cell-based assays for the 
detection of prostate cancer markers have been developed and proven to have clinical 
value (Groskopf et al., 2006; Laxman et al., 2006). Exosomes are a more recent, 
promising alternative target in urine-based assays (Nilsson et al., 2009; Dijkstra et al., 
2014). They are secreted by both normal and tumor cells, and as they lack the 
ribosomal RNA that usually makes up the bulk of RNA in cells, they can be inherently 
enriched in regard to the mRNA fraction. The challenges caused by the heterogenous 
nature of prostate cancer in tissue sampling settings could also be overcome by 
examining the exosomes that could conceivably present a more uniform image of the 
overall tumor load in the organ (Skog et al., 2008). 
2.2.2 Specimen handling 
Obtaining accurate data on mRNA levels in biological matrices relies on high-quality 
specimens, and appropriate sample collection and handling is crucial. Without 
stabilizing procedures, the RNA content of cells is quickly degraded by RNAses of 
inherent and external origins after the cells are removed from their original 
environment. Optimal preservation of RNA in excised samples can be achieved by 
snap-freezing the tissue or cell sample immediately after removal while it is still fresh, 
but, unfortunately, this is not always feasible (Srinivasan et al., 2002). Another, more 
practical option is to immerse the sample in a fixative. Guanidine thiocyanate can be 
used to deactivate RNAses and denature the proteins, while also enabling subsequent 
extraction of intact RNA from samples (Chirgwin et al., 1979). Specific reagent 
mixtures designed to stabilize RNA are also commercially available. After storage in 







RNA is of equal quality to RNA extracted from snap-frozen samples (Grotzer et al., 
2000; Florell et al., 2001). RNA in peripheral blood can be stabilized by PAXgene 
solution (Preanalytix) (Rainen et al., 2002). 
For prospective studies, the specimen collection method can be designed to fit the 
experimental protocol and aim. However, archived tissue material could be highly 
useful for retrospective studies regarding, for example, patient outcomes after several 
years, or later recurrences of the cancer. The tissue fixative most commonly used for 
histopathological purposes is formalin. Rupp and von Weisäcker and their colleagues 
were the first to detect any RNA from formalin-fixed samples by Northern 
hybridization and reverse-transcription polymerase chain reaction (RT-PCR), 
respectively (Rupp & Locker 1988; von Weizsacker et al., 1991). Since then, the 
reports on the levels of success have varied, and formalin fixation is widely known to 
affect the RNA quality. The routine protocol of archiving the formalin-fixed tissue 
embedded in paraffin (FFPE) also reduces the quantity and quality of RNA if archiving 
is prolonged (Ibusuki et al., 2013; Nam et al., 2014; Granato et al., 2014), and changes 
in RNA quality have appeared already after one month of storage (Nam et al., 2014). 
Thus, the possibilities for detection of RNA in FFPE samples are limited and only 
small RNA fragments can be amplified from FFPE tissue (Srinivasan et al., 2002). 
Amplicons of 148–200 bp in length are already long enough to be affected, and, in 
general, amplicons of 60–120 bp are recommended for robust analysis (Lewis et al., 
2001; Nam et al., 2014). 
The formalin fixation has been speculated to affect the RNA either by degrading it 
(Bresters et al., 1994); causing it to be cross-linked to proteins, thus rendering the RNA 
poorly extractable; or otherwise chemically modifying it. There are reports showing 
that fragmentation before fixation and during prolonged storage in paraffin blocks at 
room temperature can occur, but that even seemingly intact RNA can perform poorly 
in RT-PCR applications: this suggests that degradation accounts for only a portion of 
the decrease in quality (Masuda et al., 1999; von Ahlfen et al., 2007). Cross-linking to 
proteins can be reversed by treatment with proteinase K, but the greatest challenge is 
the chemical modification by formalin (Masuda et al., 1999). In the modification 
reaction, formaldehyde is attached to a nucleotide base in RNA in the form of 
monomethylol and, subsequently, the monomethylol forms a methylene bridge to 
another base by an electrophilic attack. Vulnerability to the modification has been 
found to vary for the nucleic acid bases: adenine was found to be the most and uracil 
the least easily affected. For reverse transcription, it is therefore recommended that 
random priming rather than oligo-dT primers be used, if the poly(A) tails of mRNA are 
suspected to be damaged. The methylol addition can be reversed by heating the pure 
RNA extract in a nonformalin buffer, such as TE buffer, prior to reverse transcription. 
This revives a large portion of the RNA making it an adequate template for reverse 
transcription. Not all modifications are reversible, however, and fixation methods other 
than formalin have later been suggested for fixing the tissue while simultaneously 







60% methanol, 30% chloroform, and 10% glacial acetic acid), RCL2® (Alphelys), 
Carney’s fixative (consisting of 60% ethanol, 30% chloroform, and 10% glacial acetic 
acid), and the HOPE method (Hepes-glutamic acid buffer-mediated organic solvent 
protection effect) (Srinivasan et al., 2002; Delfour et al., 2006; Nam et al., 2014). The 
recently developed PAXgene tissue system (Preanalytix) has also been tested in 
comparison to formalin fixation: it was possible to successfully amplify longer 
amplicons with the PAXgene system, but its ability to replace formalin is still under 
evaluation (Belloni et al., 2013). 
As none of the alternative methods have yet become common and, therefore, tissue 
preserved using them is not widely available for retrospective studies, researchers have 
used other approaches to be able to still utilize the existing, vast FFPE tissue archives. 
Experimental protocols have been modified to include RNA extraction kits that have 
been manufacturer-optimized for the reversal of formaldehyde effects, and short 
amplicons have been designed to maximize the possibility of an intact target region of 
RNA (Walter et al., 2013; Gruber et al., 2014). To ensure data reliability, specific 
criteria for nucleic acid quality have been used to exclude samples with inadequate 
quality (Korlimarla et al., 2014). 
2.2.3 Accurate quantification of mRNA transcripts 
To ensure the identification of the relevant aberrations in gene expression in disease 
conditions, reliable quantitative data on the transcript levels are required. As reviewed 
by Bustin (2000), there are five techniques in use for the quantification of mRNA 
transcript levels: Northern blotting; in situ hybridization; RNA protection assays; 
complementary DNA (cDNA) arrays; and the most widely used, RT-PCR. However, 
the first three are limited in their ability to produce quantitative data, and nucleic acid 
amplification techniques are required for sensitive, yet quantitative analyses. 
Polymerase chain reaction (PCR), developed by Kary Mullis and first reported in 1985 
(Saiki et al., 1985), is the most widely used amplification method for nucleic acids and 
it is able to produce multiple copies from one or several DNA fragments in a 
thermocyclic reaction. Coupling the technique with reverse transcriptase enzyme 
retrieved from retroviruses enables also the amplification of RNA (Rappolee et al., 
1988). The invention of reporter systems based on detection chemistries involving 
fluorescent probes enabled researchers to evade the problems in end-point 
measurements related to the variable linearity of amplification, and produce accurate 
data on the amounts of amplification products in real-time. Oligonucleotide probes 
coupled to fluorescent labels – Molecular beacons (Tyagi & Kramer 1996), 
hybridization probes (Wittwer et al., 1997; Karhunen et al., 2011), or hydrolysis 
probes (Livak et al., 1995; Nurmi et al., 2002) – allow for the sensitive and specific 
detection of the amplification products, whereas the SYBR® Green technique 








However, to obtain a true idea of the gene expression in the specimen at the time of 
specimen collection, the target-specific transcript level data need to be normalized and 
corrected for potential RNA degradation and other variables in the multistep assay 
protocol. Relative quantification is widely used and takes advantage of reference 
genes, previously referred to as house-keeping genes. They are assumed to be 
transcribed at a fixed level in all conditions and in this approach, the target gene 
expression levels are reported as ratios to the expression level of the reference gene. 
Beta-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are two of the 
most commonly used reference genes (Bustin 2000). The reliability of this 
normalization method has often been questioned due to the reported changes in the 
expression of the reference genes in disease conditions, and their instability in FFPE 
tissues during storage (Tramm et al., 2013; Li & Shen 2013). Therefore, the validation 
of the chosen reference genes for the desired application is highly essential, and the use 
of more than one gene is recommended. An alternative, potentially excellent method 
for internal reference is the use of artificial RNA that cannot be found in the specimens 
inherently (Nurmi et al., 2000b; Huggett et al., 2005). An addition of a fixed amount of 
the internal reference RNA to the sample before RNA extraction process allows the 
later detection of the internal RNA by RT-PCR, and subsequent normalization of the 
target mRNA level to the internal reference level. An advantage is that the standard 
level does not change according to sample characteristics, such as neoplasticity of the 
cells. However, the production of artificial RNA is an extra step of labor for the 
research laboratories and, furthermore, even this internal reference cannot control the 
changes in the sample before the addition of the reference, i.e. during sample collection 
and storage. In the absence of a reliable, trustworthy internal reference, research groups 
have sometimes opted to use total RNA concentration as the tool for normalization 
(Bustin 2000). This is not entirely without pitfalls either, as highly proliferating cells 
can produce large amounts of RNA, the bulk of which is composed of ribosomal RNA 
and the amount of ribosomal RNA can be affected by biological factors. 
2.3 Finding biomarkers for prostate cancer: suggested mRNA 
transcripts 
Proteomics and genomic microarray studies have increasingly provided the researchers 
with new candidate genes to examine more closely for potential usefulness in cancer 
diagnostics. The expression of the genes can be measured on translational level by 
detecting proteins, or on transcriptional level by examining mRNA transcripts. Proteins 
can quickly become degraded or they may be ineffectively translated and, therefore, an 
increase in mRNA level may not lead to higher protein levels, and high protein 
expression may not occur simultaneously with high mRNA levels. Consequently, the 
observations of a specific gene can vary based on the target molecule. This chapter 
discusses the hitherto reported mRNA transcript level data on the target genes that 
were examined in this doctoral work. The target mRNAs include a non-coding RNA, a 







proteases, cell membrane components, and growth factors. The 12 target genes are 
presented in alphabetical order. 
2.3.1 BMP-6 (bone morphogenetic protein 6) 
Prostate cancer metastasizes predominantly to the bone. Bone morphogenetic protein 6 
(BMP-6) is a gene that codes for a protein acting as a factor in bone tissue formation 
(Wozney 1989). It belongs to the TGF (transforming growth factor) -beta superfamily 
of growth factors (Celeste et al., 1990), and normally plays a role in mesechymal 
differentiation initiating the osteoblastic differentiation of pluripotent precursor cells 
(Gitelman et al., 1995). The BMP-6 gene is located in chromosome 6p23-p24 (Hahn et 
al., 1992; Olavesen et al., 1997). 
Using end-point RT-PCR, BMP-6 mRNA was found to be expressed in the prostate 
tissue of 32% of the 19 men with prostatic adenocarcinoma, but not in the 12 studied 
BPH tissues or 10 controls with ocular melanoma (Bentley et al., 1992). The results 
were later repeated with in situ hybridization (Hamdy et al., 1997). However, there are 
also reports on BMP-6 mRNA present in normal prostate tissue but at lower expression 
levels than in cancerous regions (Harris et al., 1994; Barnes et al., 1995). The 
relationship of BMP-6 mRNA transcripts and prostate cancer has not been extensively 
studied, but its potential role in metastatic cancer has garnered particular interest. In the 
early study by Bentley and colleagues, BMP-6 was the only one of the several studied 
BMP genes that had a detectable mRNA expression exclusively in patients with 
skeletal metastases. Of the cohort of 19 patients mentioned above, 11 were positive for 
metastases in bone scans and 55% of the 11 expressed BMP-6 mRNA (Bentley et al., 
1992). Another, more recent report also showed that BMP-6 mRNA was found in 
metastatic cancers at a higher frequency compared to localized diseases (Hamdy et al., 
1997).  
Higher levels of circulating BMP-6 mRNA were found in the post-treatment plasma of 
patients with metastases, than in patients with a locally confined disease, but a similar 
trend was not seen in the blood cells of the same patients (Deligezer et al., 2010). 
Lately, the research interests have concentrated on the effect of BMP-6 on cell 
proliferation rather than clinical studies regarding prostate cancer. 
2.3.2 FGF-8b (fibroblast growth factor 8, isoform b) 
Growth factors are signaling molecules needed for the cell growth and proliferation. 
FGF-8 (fibroblast growth factor 8) gene is situated in chromosome 10q24 and codes 
for a protein belonging to the FGF superfamily of growth factors (Yoshiura et al., 
1997). FGF-8 protein functions as a mitogenic embryonic epithelial factor, and in 
adults it is expressed predominantly in testes and ovaries (Payson et al., 1996). The 
physiological levels of FGF-8 products in cells are thought to be low in general, as in 







blotting was not able to detect expression in adult prostate, kidneys or testes (Ghosh et 
al., 1996). 
FGF-8 was previously known as AIGF, androgen-induced growth factor, and it has 
been shown to be capable of inducing the growth of cancerous mammary cell lines of 
both human and mouse origin if androgens are supplied (Tanaka et al., 1992; Payson et 
al., 1996). However, androgen-independent control mechanisms of FGF-8 expression 
may also exist, because some studies failed to show a regulating role for androgen in 
the FGF-8 expression (Schmitt et al., 1996), even in the lymph node-derived prostate 
carcinoma cell line LNCaP that is androgen-driven (Ghosh et al., 1996). Additionally, 
DU145 and PC3 cell lines, derived from brain and bone metastases, respectively, lack 
the androgen receptor, but were found to be positive for FGF-8 mRNA (Ghosh et al., 
1996; Schmitt et al., 1996). 
Dorkin and colleagues (1999) found by in situ hybridization that FGF-8 mRNA was 
present in 80% of the studied 106 prostate cancer cases, and that the increased 
expression was associated with a higher Gleason score and an advanced tumor stage. 
Leung and colleagues (1996) also found a correlation between high FGF-8 mRNA 
levels and a poor differentiation of cells. In contrast, Wang and colleagues (1999) 
found FGF-8 mRNA expression in all 14 BPH samples and in 87% of the 39 tumor 
samples, and indicated a negative correlation between FGF-8 mRNA expression and 
the Gleason grade (Wang et al., 1999). The initial expression detected by in situ 
hybridization was confirmed in a subgroup of samples with RT-PCR.  
The human FGF-8 gene consists of six exons. The identification of the four mRNA 
variants – a, b, e, and f – and seven protein products (Crossley & Martin 1995; 
MacArthur et al., 1995b; Ghosh et al., 1996) resulting from an alternative splicing of 
the first exon has enabled more targeted experiments, and it has led to the discovery 
that particularly the isoform b is implicated in prostate cancer. While FGF-8b protein 
has the strongest tumorigenic and transforming abilities of the isoforms (Ghosh et al., 
1996; MacArthur et al., 1995a), FGF-8b expression has rarely, if ever, been measured 
at mRNA level in any clinical cohorts relating to prostate cancer. 
2.3.3 Kallikrein-related peptidases 2, 3, 4, and 15 
The human tissue kallikrein gene family consists of 15 members and they are situated 
in tandem in the chromosomal locus 19q13.4 as depicted in Figure 1 (Yousef & 
Diamandis 2001). It has been shown that the serine proteases encoded by these genes 
are able to degrade extracellular matrix components as well as produce mitogenic 
factors, and are, therefore, able to facilitate the growth of tumors in addition to their 
normal functions (Obiezu & Diamandis 2005). They all consist of five exons 
interspersed with four introns, and contain a signal peptide encoded within the first 







KLK15 – were studied in this doctoral work, and therefore prior research especially 
concentrating on them is discussed here.  
The expression of KLK2 and KLK3 is mostly restricted to prostate, while KLK4 and 
KLK15 are more widely expressed among human tissues and body fluids (Shaw & 
Diamandis 2007). As reviewed by Lawrence and colleagues, especially KLK2 and 
KLK3 are upregulated by androgen in the prostate, and preliminary data existing on 
KLK4 and KLK15 suggest that they are also under androgen regulation. The expression 
in prostate is highest for KLK2 and KLK3, with KLK4 and KLK15 exhibiting lower 
levels of expression (Lawrence et al., 2010; Obiezu et al., 2002). Single nucleotide 
polymorphisms (SNPs) located within KLK2, KLK3, KLK4, and KLK15 have been 
identified and associated with prostate cancer (Pal et al., 2007; Gallagher et al., 2010; 
Batra et al., 2011; Lose et al., 2012). The SNPs have been demonstrated to correlate 
with for example decreased risk of prostate cancer, biochemical relapse or disease-
specific survival.  
 
Figure 1. The kallikrein locus in chromosome 19q13.4. The locus spans approximately 300 kb 
and consists of the 15 kallikrein genes and one pseudogene (ψ1). The arrows indicate the 
direction of gene transcription. Figure modified from (Borgono & Diamandis 2004). 
2.3.3.1 KLK2 (kallikrein-related peptidase 2) 
For the KLK2 gene, earlier known as human glandular kallikrein-1 (hGK-1), seven 
mRNA variants have been described (Kurlender et al., 2005). KLK2 expression has 
been detected in breast and other tissues, but it is predominantly expressed in prostate 
(Lawrence et al., 2010). The biological function of KLK2 includes ensuring sperm 
motility after ejaculation through the exertion of its protease activity on the proteins 
responsible for clotting the seminal matter (Deperthes et al., 1996). The KLK2 protein 







in prostate cancer diagnosis as a part of a multi-kallikrein panel (Vickers et al., 2008; 
Vickers et al., 2010).  
KLK2 is claimed to be upregulated at the transcriptional level in cancerous prostate 
tissue in comparison to BPH tissue. This has been shown by semiquantitative RT-PCR 
(Neves et al., 2008) and in situ hybridization (Herrala et al., 2001). In situ 
hybridization studies and Northern blotting analyses comparing KLK2 and KLK3 
mRNA levels in prostate tissue have shown that the KLK2 expression is about two to 
ten times lower than that of KLK3 (Chapdelaine et al., 1988; Henttu et al., 1990; 
Young et al., 1992). Lintula and colleagues (2005) showed by RT-PCR that the 
KLK2/KLK3 mRNA ratio increases in cancer tissue, and in the light of KLK3 mRNA 
expression remaining fairly constant through neoplastic development as described in 
Chapter 2.3.3.2, these data, also, imply an increase in the KLK2 expression in cancer. 
In a study examining the ability of KLK2 mRNA transcripts to serve as surrogates for 
prostate cells in the peripheral blood, a good concordance was seen between the 
quantitative RT-PCR (qRT-PCR) assay results and the CellSearch® method (Veridex) 
that has been approved by the United States Food and Drug Administration (FDA) for 
clinical use. KLK2 mRNAs were found in 49% of the 76 patients with metastatic 
castration-resistant prostate cancer, but only in 8% of the 180 men with localized 
cancer and never in healthy controls (Helo et al., 2009). 
2.3.3.2 KLK3 (kallikrein-related peptidase 3) 
The protein product of the KLK3 gene was identified in the 1970s (Hara et al., 1971; 
Wang et al., 1979) and proposed for prostate cancer diagnostics in 1980 (Papsidero et 
al., 1980). According to the current kallikrein nomenclature, the protein is called 
KLK3, but the more widely-known name PSA is used in this thesis for practical 
reasons. Since its discovery, PSA has become the biomarker of choice for prostate 
cancer detection and management, despite its certain shortcomings that have been 
described in more detail in Chapter 2.1.5. Similar to KLK2, the main physiological 
function of PSA is to liquefy the seminal clot by hydrolysing the proteins in it (Lilja 
1985).  
The KLK3 gene was first sequenced in 1989 (Henttu & Vihko 1989; Lundwall 1989; 
Riegman et al., 1989) and eleven different mRNA splice variants have been identified 
(Kurlender et al., 2005). The transcriptional level of KLK3 expression in prostate tissue 
has been studied by Northern blotting and in situ hybridization and KLK3 mRNA 
levels have been reported to be unchanged or slightly decreased in cancerous prostate 
tissue. Using tissue samples of 51 patients, Meng and colleagues (2002) reported an 
approximately 1.5 times lower KLK3 mRNA expression in the cancerous regions than 
in benign epithelium. When compared to benign hyperplastic tissue, tendencies 







been statistically significant (Henttu et al., 1990; Hakalahti et al., 1993; Herrala et al., 
2001). 
The expression of KLK3 is largely restricted to the prostate, but low levels have been 
found also in salivary glands, as well as in breast and brain tissues (Lawrence et al., 
2010). The prostate-specific expression of KLK3 indicated a possibility to use it as a 
molecular tool for prostate cancer diagnosis and staging by detecting prostate-specific 
circulating tumor cells in blood. After the promising initial results by Katz and Moreno 
and their colleagues, where transcripts were found in 33–78% of the localized or 
metastasized cancers but never in cancer-free controls (Moreno et al., 1992; Katz et al., 
1994), later studies have produced contradictory data with KLK3 mRNAs present also 
in the healthy category (Henke et al., 1997; Thiounn et al., 1997). Methodological 
aspects and factors related to sample cohorts and processing may have contributed to 
the discrepancies between the studies, and sometimes an increased sensitivity has been 
speculated to be the cause for the seemingly false positives in the controls. However, 
with a sensitive qRT-PCR assay (and similarly to KLK2 transcripts as described in 
Chapter 2.3.3.2), KLK3 mRNAs have been shown to serve as good markers for 
prostatic cells in the blood of prostate cancer patients. The transcripts were only 
detected in localized and metastatic cancer cases and the results were in concordance 
with findings achieved with the CellSearch® method (Veridex) (Helo et al., 2009). 
2.3.3.3 KLK4 (kallikrein-related peptidase 4) 
KLK4 gene was originally characterized by Nelson and colleagues (1999), and at the 
time, its protein product was called prostase. Its biological role in humans is not fully 
clarified but has been suggested to be involved in tooth formation (Borgono et al., 
2004). At the protein level, it is claimed to be expressed in very small amounts in 
normal and neoplastic prostates (Obiezu et al., 2002).  
It has sometimes been suggested that the first kallikrein exon is not part of the 
functional gene as far as KLK4 is concerned. There are reports that indicate that it 
would, therefore, be missing the signal peptide and have an intracellular, instead of a 
secretory, function (Korkmaz et al., 2001; Xi 2004). KLK4 is transcribed into at least 
nine different mRNA variants (Nelson et al., 1999; Kurlender et al., 2005). 
Additionally, a chimeric sense-antisense transcript has been identified (Lai et al., 
2010).  
In addition to prostate, KLK4 mRNA expression has been found at low to moderate 
levels in other tissues including adrenal, salivary, and thyroid glands, and small 
intestine (Nelson et al., 1999; Day et al., 2002). Using qRT-PCR, Day and colleagues 
showed initially that KLK4 mRNA levels are equally upregulated in both normal and 
cancerous prostate tissues compared to the other normal human tissues. However, later 
studies with an in situ hybridization analysis of 118 tissue microarrays (Xi 2004) and a 







cancerous tissues compared to normal, PIN, and BPH tissues (Avgeris et al., 2011). 
The Avgeris study also demonstrated a positive correlation between high KLK4 mRNA 
levels and cancer stage, but found no connection to Gleason score. 
2.3.3.4 KLK15 (kallikrein-related peptidase 15) 
KLK15 is one of the later discovered kallikreins and its biological role has not been 
clarified yet. In addition to prostate, KLK15 mRNA transcripts have been found in 
salivary glands, testes, kidneys, colon, adrenals, and thyroid gland (Yousef et al., 
2001). The initial semiquantitative RT-PCR analyses revealed elevated KLK15 mRNA 
levels in 45% of the 29 studied pairs of cancerous and matched noncancerous prostate 
tissue, and only three pairs showed lower KLK15 mRNA levels in the cancerous 
counterpart. This was later repeated with qRT-PCR by Stephan and colleagues, using 
90 matched cancer-noncancer tissue pairs of which 84% showed upregulation in 
cancer. They also demonstrated an association of higher KLK15 expression with higher 
pathological stage (Stephan et al., 2003). 
The KLK15 gene is alternatively spliced and at least six splice variants have been 
identified (Yousef et al., 2001; Kurlender et al., 2005). In an experiment evaluating the 
differential tissue expression of the classical variant and three additional transcript 
variants separately, Mavridis and colleagues showed that only the classical variant was 
overexpressed in cancer (Mavridis et al., 2010). The same isoform was later 
specifically associated with pathological stage (Mavridis et al., 2013). Higher KLK15 
levels correlated with a higher pathological tumor stage and Gleason score also in a 
study of 25 pairs of cancerous and matched noncancerous tissue from radical 
prostatectomies, regardless of the variant type as the amplicon used in the qRT-PCR 
assay enabled the detection of all KLK15 mRNA variants (Rabien et al., 2010).  
2.3.4 MSMB (microseminoprotein, beta) 
The gene MSMB (microseminoprotein, beta) is located in chromosome 10q11.2 (Sasaki 
et al., 1996). It codes for the cysteine-rich beta-microseminoprotein (MSP) that has 
also been called PSP94 (prostate secretory protein of 94 aminoacids) or beta-inhibin 
(Ulvsback et al., 1989). It is one of the three most abundant proteins secreted by the 
epithelial cells of the prostate (Lilja & Abrahamsson 1988), and it has high prostate 
specificity but also low expression in cervix (Baijal-Gupta et al., 2000), respiratory 
tissues such as lung tissue (Ulvsback et al., 1989), and mucosal fluids such as tears and 
saliva (Weiber et al., 1990). Within the prostate, the expression of MSMB varies 
depending on the zone, with the highest levels in the peripheral zone where, perhaps 
not incidentally, most prostate tumors are found (Chan et al., 1999). 
At protein level, decreased MSP concentrations in serum have been linked with 
prostate cancer, as reviewed by Whitaker and colleagues (2010). Similar trends have 







the protein and mRNA levels of MSMB do not always correlate, even in tissue 
(Tsurusaki et al., 1998), and the discrepancies could be explained by differences in the 
half-lives of the protein and mRNAs, or the fact that the degraded forms of mRNA fail 
to be detected by the assays. 
The mRNA expression of MSMB in prostate tissue has been examined by both in situ 
hybridization and qRT-PCR techniques using radical prostatectomy samples or needle 
biopsies. The majority of studies have found MSMB mRNA levels to be lowered or the 
mRNA to be absent in malignant tissue compared to benign samples. Vanaja and 
colleagues measured MSMB mRNA levels in 32 cancerous prostate tissues with qRT-
PCR based on the Taqman method, and using GAPDH as a reference gene (Vanaja et 
al., 2003). They found MSMB to be downregulated in malignant tissue compared to the 
12 adjacent benign tissues and, furthermore, in metastatic cases compared to organ-
confined cancers. Three in situ hybridization studies have come to the same 
conclusion. Chan and colleagues (1999) found a decrease in MSMB expression in a 
cohort of five tumor samples compared to 27 benign prostate tissues. The other two in 
situ hybridization studies were conducted by a group in Nagasaki, Japan, finding 63/92 
and 72/104 cancerous prostate biopsies negative for MSMB mRNA, respectively 
(Tsurusaki et al., 1998; Sakai et al., 1999). The control tissues, five in each study, were 
always positive for MSMB mRNA expression. However, neither study found a 
correlation between MSMB expression and clinical stage or Gleason grade. Different 
MSMB mRNA variants have been identified and in a qRT-PCR study, the variant 
MSMB1 was reported to be the predominant form in malignant prostate tissues whereas 
MSMB2, the variant lacking the exon 3, was primarily expressed in benign tissues 
(Harries et al., 2010). 
MSP has been shown to play a role in regulating cell apoptosis in normal cells, and 
therefore its loss in cancer could be postulated to lead to uncontrolled cell proliferation 
(Garde et al., 1999). This would indicate that advanced, metastatic prostate cancers 
would lack MSMB expression, but in fact, prostate cancers with high MSMB expression 
have been linked to shorter progression-free survival (Sakai et al., 1999). This is rather 
unexpected, but despite having been contradicted by the Vanaja study described above 
(Vanaja et al., 2003), the finding is supported by MSMB expression having been found 
in prostate cancer cell lines LNCaP and PC3, both deriving from metastatic origins 
(Yang et al., 1998a; Yang et al., 1998b). Nevertheless, androgen-deprivation therapy 
decreases MSMB mRNA levels in prostate tissue (Dahlman et al., 2010). 
MSMB mRNA has been shown to have potential use as a urine-based biomarker. In a 
study cohort of 91 prostate cancer patients and 85 men with BPH or prostatitis, and 
using qRT-PCR with the LightCycler method and the normalization of the data 
towards a reference gene, MSMB was found to be able to discriminate the cancer cases 
from other prostatic diseases as a part of a duplex model with TRPM8, a triplex model 
with TRPM8 and AMACR, or a quadriplex model with TRPM8, AMACR, and PCA3 







Serum MSP levels can be influenced by genetic variance, and a SNP located upstream 
of MSMB gene in chromosome 10q11.2 has been associated with prostate cancer 
(Eeles et al., 2008; Thomas et al., 2008). The low risk allele has a C instead of a T at 
the location rs10993994. It could account for the differences in MSP levels in serum as 
the CREB (cAMP response element-binding) transcription factor binds preferentially 
to the low risk allele, leading to higher MSP levels (Chang et al., 2009; Waters et al., 
2010; Dahlman et al., 2010). The risk allele T is shown to be present in 40% of 
Caucasians (Eeles et al., 2008; Thomas et al., 2008) and 60% of African-Americans 
(Chang et al., 2011), perhaps partly accounting for the higher prevalence of prostate 
cancer observed in the African-American population. 
2.3.5 PCA3 (prostate cancer antigen 3) 
The majority of the human genome, 80%, is transcribed into RNA molecules without 
protein-coding potential. If the molecules are longer than 200 nucleotides in length, 
they are called long noncoding RNAs (lncRNAs). Molecules shorter than that belong 
to small noncoding RNAs, and microRNAs (miRNAs) that are only 20-22 nucleotides 
long are one of their most studied subgroups. Noncoding RNAs have been shown to 
function as regulators of gene expression and cellular functions. LncRNAs can often be 
found in the nucleus, where they regulate gene expression epigenetically by binding to 
chromatin remodeling complexes, and for example miRNAs can act as negative post-
transcriptional regulators (Martens-Uzunova et al., 2014). PCA3 (prostate cancer 
antigen 3) is a gene that is found to be transcribed into a lncRNA associated with 
prostate cancer. PCA3 was discovered in 1999 and was first named DD3 (differential 
display 3) according to the discovery technique (Bussemakers et al., 1999). It has been 
mapped to chromosome 9q21.22, and its RNA product is currently, despite research 
efforts, not known to code for any functional protein, as it has very short open-reading 
frames. PCA3 transcripts have been localized to the nucleus (Schalken et al., 2003) and 
a study with small interfering RNAs (siRNAs) has indicated a potential role for PCA3 
in the regulation of androgen receptor target genes (Ferreira et al., 2012). Initially, the 
PCA3 gene was described to comprise of four exons (Bussemakers et al., 1999), with 
two additional ones discovered ten years later (Clarke et al., 2009). Alternative splicing 
of the gene occurs, with the predominant transcript consisting of exons 1, 3, 4a and 4b 
(Bussemakers et al., 1999). 
Already in the initial studies, the expression of PCA3 was demonstrated to be 
predominantly prostate-specific as no expression was detected even by RT-PCR in any 
of the other cancer types studied or in the 18 normal human tissue types, with the 
exception of low levels in kidney tissue (Bussemakers et al., 1999; de Kok et al., 
2002). The absence of PCA3 transcripts in leukocytes suggested potential usefulness in 
detecting prostate cells in bodily fluids such as blood and urine (de Kok et al., 2002). 
Using Northern blotting, the upregulation of PCA3 was associated with prostate cancer 







nonneoplastic tissue, even though low levels of PCA3 RNA were seen in normal 
prostate and BPH tissue with RT-PCR. Since then, variable magnitudes of PCA3 RNA 
overexpression have been reported in cancerous prostate tissue, ranging from 10 to 
100-fold upregulation (Bussemakers et al., 1999; de Kok et al., 2002; Hessels et al., 
2003; Robert et al., 2013), or 6–1500-fold overexpression in individual matched cases 
(Hessels et al., 2003). The observations are summarized in Table 3. In a review by 
Schalken and colleagues, the PCA3 RNA copy levels are reported to be 3.2 x 102–8.5 x 
105 copies/µg RNA in normal prostate or BPH tissue, and 5.3 x 104–1.4 x 108 
copies/µg RNA in cancerous tissue (Schalken et al., 2003). 
Table 3. Magnitudes of PCA3 overexpression observed in cancerous prostate tissue. 
Reference Carcinoma 
samples (n) 
Control samples (n) Method of 
analysis 
Magnitude of PCA3 
overexpression 
Bussemakers 
et al., 1999 





de Kok et al., 
2002 
31 11 benign tissues from PCa 
patients + 5 BPH from PCa 
patients 
qRT-PCR 34-fold 






4 benign tissues from RP 
specimens + 8 BPH 
qRT-PCR 66-fold 
 13 (containing 
less than 10% 
cancer cells) 
4 benign tissues from RP 
specimens + 8 BPH 
qRT-PCR 11-fold 
 7 Benign tissues from the same 
PCa patients 
qRT-PCR 6–1500-fold 
Robert et al., 
2013 
48 32 benign tissues from PCa 
patients 
qRT-PCR 30-fold 
PCa, prostate cancer; BPH, benign prostatic hyperplasia; qRT-PCR, quantitative reverse-
transcription PCR; PCA3, prostate cancer antigen 3. 
The promising initial and subsequent data on the prostate cancer specificity of PCA3 
generated a lot of interest in the field, and subsequently led to a commercial application 
of a noninvasive urine-based test for PCA3 RNA levels, currently offered under the 
brand name of PROGENSA® PCA3 (Gen-Probe) (Groskopf et al., 2006). It measures 
the PCA3 RNA content of cells in a post-DRE urine sample. The DRE procedure has 
been shown to increase the dissociation of the prostate cells into urine, and the 
informative rate (the percentage of samples having enough prostate cells to warrant the 
molecular analysis) increases from 80% to 95% with DRE (Day et al., 2011). The 
presence of prostate cells is controlled in the PCA3 test by measuring the KLK3 mRNA 







PROGENSA® PCA3 test was launched as a semiquantitative, commercially available 
test in Europe in 2006 and received approval from the United States FDA in 2012. It is 
performed on whole urine, and the analysis is based on capturing the target RNAs with 
magnetic beads, followed by transcription-mediated amplification of the RNAs, and 
the detection of the amplification by chemiluminescent probes. The urine 
centrifugation and RNA extraction steps can be bypassed using this protocol, and the 
voided urine is stored in an equal volume of detergent-based stabilization buffer, 
enabling the freezing of the sample. The test detects an amplicon that spans the 
junction of exons 3 and 4a, thereby recognizing all of the known PCA3 transcripts 
(Groskopf et al., 2006). 
In cohorts of 108 and 517 men, the first and second-generation versions of the 
PROGENSA® PCA3 test, respectively, produced sensitivity and specificity values of 
66–82% and 76–89% (Hessels et al., 2003; Fradet et al., 2004; Tinzl et al., 2004). The 
concept of the PCA3 score, the ratio of PCA3/KLK3 transcripts multiplied by a factor 
of 1000, obtained from the 3rd generation PCA3 test was first introduced by Groskopf 
and colleagues (Groskopf et al., 2006) and reported under that name by van Gils and 
colleagues (van Gils et al., 2007). These studies demonstrated sensitivities of 65–69% 
and specificities of 66–79%. Since then, the performance of the PROGENSA® PCA3 
test has been validated in diverse laboratories, and higher median PCA3 scores in men 
with prostate cancer have been repeatedly demonstrated (Marks et al., 2007; Haese et 
al., 2008; Deras et al., 2008; Aubin et al., 2010). Notably, the test also produces 
consistently better area under the curve (AUC) values in receiver operating 
characteristic (ROC) analyses than those obtained with serum PSA levels for the same 
cohorts (Marks et al., 2007; Haese et al., 2008), but the scores are associated with 
prostate volume unlike serum PSA (Haese et al., 2008; Deras et al., 2008). As 
reviewed by Day and colleagues, the PCA3 score contributes to improved diagnostic 
accuracy in multivariate models (Day et al., 2011). The correlation between PCA3 
score and high-grade PIN found at biopsy is still under investigation due to 
contradictory data (Deras et al., 2008; Haese et al., 2008). The prognostic value of 
PCA3 score is also still unclear, as studies have reported varying results on the 
association with Gleason score and tumor volume (Haese et al., 2008; van Gils et al., 
2008; Nakanishi et al., 2008). 
Initially a PCA3 score of 35 was recommended as the cut-off point for an increased 
risk of having cancer at repeat biopsy (Marks et al., 2007; Haese et al., 2008). Using 
this cut-off of 35, sensitivities of 48–58% and specificities of 72–79% have been 
reported (Marks et al., 2007; Haese et al., 2008; Deras et al., 2008; Aubin et al., 2010). 
The FDA-approved test uses a cutoff of 25, but also other cut-off values have been 
suggested to avoid false negative results (de la Taille et al., 2011; Crawford et al., 
2012). However, there are also recent studies by Schröder and colleagues 
demonstrating that cohorts of men with PCA3 scores ≥100 can show surprisingly low 
rates of detected cancers, even after several rounds of biopsies and a magnetic 







low as 11% were seen in a cohort of 62 men. Earlier, the risk of having a positive 
biopsy was reported to be 46–89% in men with PCA3 scores over 100 (Marks et al., 
2007; van Gils et al., 2007; Deras et al., 2008; Haese et al., 2008; Shappell et al., 
2009). It has been speculated that abnormally high PCA3 scores in seemingly cancer-
free men may be caused by the upregulation of PCA3 in precursor lesions, or simply 
cancers missed by biopsy (Schröder et al., 2014). In fact, PCA3 expression has been 
detected by in situ hybridization more frequently in benign glands that are in closer 
proximity to the tumor than in glands further away, demonstrating that alterations in 
PCA3 expression can appear in benign regions in association with or anticipation of 
cancer (Popa et al., 2007). This could be explained by the field cancerization theory, 
i.e., that molecular aberrations are not limited to the tumor focus but may be present in 
a larger region (Slaughter et al., 1953). 
A small number of studies have attempted the detection of PCA3 transcripts in 
circulating tumor cells in peripheral blood. Immunomagnetic enrichment was used to 
increase sensitivity in studies by Shaw and colleagues, and Jost and colleagues (Shaw 
et al., 2008; Jost et al., 2010). Both found PCA3 RNA in blood of men with advanced 
or castration-resistant prostate cancer. All studied men presented PCA3 transcripts in 
the Shaw study, and also one of the healthy controls did so as well, albeit at a low 
level. In the Jost study, no PCA3 transcripts were found in cases of androgen-
dependent cancers. Studies performed without a cell enrichment step have reported 
PCA3 RNA findings in blood at least twice. Nested RT-PCR combined with a 
densitometric analysis of the amplification products from an agarose gel detected 
PCA3 RNA in 14/84 cancer cases, 13/65 men with BPH, and one out of 11 studied 
men with PIN diagnosis (Marangoni et al., 2006). In a later study using a similar 
method, PCA3 transcripts were found in the blood of 28/57 men with T1–T3 stage 
prostate cancer and 6/110 healthy individuals (Neves et al., 2013). Surprisingly, the 
positivity rate, especially among cancer-free men, was higher in the studies where cell 
enrichment was not used. This may be related to other methodological aspects or, as 
speculated by the authors, a sign of a cancer risk in the future. 
2.3.6 PSCA (prostate stem cell antigen) 
PSCA (prostate stem cell antigen) gene is located in chromosome 8q24.2 and it codes 
for a cell surface glycoprotein that was identified as a candidate biomarker for prostate 
cancer in 1998 (Reiter et al., 1998). The mRNA expression of PSCA was deemed to be 
prostate-specific after analyses with Northern blotting and RT-PCR showed that it is 
predominantly found in prostate with only low level expression in placenta, kidneys, 
and small intestine. The physiological function of PSCA protein remains unknown 
(Saeki et al., 2010; Bargão & Patel 2014). 
In prostate, PSCA mRNA expression was shown by in situ hybridization to be 
localized to the basal cell layer of the epithelium, and 88% of the 126 cancerous 







or moderately for PSCA mRNA, while normal glands of the same specimens stained 
only weakly or not at all (Reiter et al., 1998). However, later studies, also performed 
with in situ hybridization techniques, have contradicted the results of the pilot study 
and showed that PSCA mRNA can also be found in the secretory luminal cells (Ross et 
al., 2001; Ross et al., 2002; Zhigang & Wenlv 2004) and, in fact, also in normal areas 
of the prostate, without apparent association between the expression level and the 
tissue morphology (Ross et al., 2001; Ross et al., 2002). The later reports also disagree 
on the association of the neoplasticity of the cells with the levels or frequencies of 
PSCA mRNA expression. A study by Ross and colleagues found no apparent 
association between the expression level and tissue morphology (Ross et al., 2002), but 
another study reported higher expression levels in prostate cancer and high-grade PIN 
tissue compared to those in BPH or low-grade PIN tissue (Zhigang & Wenlv 2004). 
Both studies were performed with in situ hybridization. A study utilizing the more 
sensitive qRT-PCR method did not find statistically significant differences between 
PSCA mRNA levels in cancerous and matched nonmalignant prostate tissue (Schmidt 
et al., 2006b). 
PSCA mRNA has not been detected in the peripheral blood of healthy individuals, but 
the prevalence in men with prostate cancer varies from 10 to 32% (Hara et al., 2002; 
Joung et al., 2007; Helo et al., 2009; Zhao et al., 2012). Hara and colleagues 
determined the expression of PSCA mRNA in the circulating tumor cells in prostate 
cancer patients by nested RT-PCR combined with detection from agarose gel, and 
found it in the blood of 13.8% of the 58 studied prostate cancer patients but in none of 
the blood specimens from 71 men with nonmalignant diseases (Hara et al., 2002). In 
2007, PSCA mRNA was detected also with RT-PCR in the peripheral blood of 13.6% 
of 66 prostate cancer patients. A significantly higher number of those patients had 
high-grade cancer or non-organ-confined cancer than low-grade or organ-confined 
disease, and it was concluded that PSCA mRNA in blood could help in the molecular 
staging of prostate cancer (Joung et al., 2007). The qRT-PCR assay developed in this 
doctoral work has also been used elsewhere for determining PSCA mRNA-positive 
cells in the blood of prostate cancer patients, and 10% of castration-resistant stage 
patients were found to be positive for PSCA mRNA (Helo et al., 2009), whereas the 
transcripts were undetectable in cases of localized cancer and in healthy volunteers. 
Zhao and colleagues recently detected PSCA mRNA in the blood of 31.9% of 116 
patients with locally advanced or metastatic disease but in none of the 40 healthy 
volunteers (Zhao et al., 2012). 
Zhigang and colleagues have studied the role of PSCA mRNA as a predictor of cancer 
development. With in situ hybridization, they noticed that PSCA mRNA expression in 
the PIN or BPH tissue of a cancer-free prostate predicted a later development of 
prostate cancer (Zhigang & Wenlu 2007; Zhigang & Wenlu 2008). A cohort of 288 
BPH cases with serum PSA levels under 4.0 ng/mL were followed for up to 70 months, 
and 23.7% of the 93 originally PSCA-positive patients developed cancer during the 







Wenlu 2008). A cohort of 166 BPH patients that were considered to have an increased 
cancer risk and had serum PSA levels higher than 4.0 ng/mL demonstrated even more 
remarkable results: 73.8% of the 42 patients who had been PSCA mRNA-positive at 
the preoperative biopsy at the beginning of the study, developed prostate cancer during 
the study period of five years, whereas none of the 124 PSCA-negative patients 
developed cancer (Zhao et al., 2009). In a cohort of 117 men with PIN at initial biopsy, 
there was a significantly higher frequency of PSCA mRNA expression observed in the 
high-grade PIN specimens compared to the low-grade PIN samples, and the expression 
was significantly elevated in those men that subsequently developed cancer (Zhigang 
& Wenlu 2007). Thirty-four cases overall developed cancer during a follow-up time of 
up to 85 months and all cancer cases expressed PSCA. The subsequent cancer was 
significantly more likely to develop if the original specimen was PSCA mRNA 
positive. 
There are indications that the blood level of PSCA mRNA may perform as a predictor 
of biochemical relapse. Joung and colleagues were able to detect PSCA mRNA in the 
blood of 17 of the 103 studied prostate cancer patients before their curative radical 
prostatectomies, and they monitored the patients for up to 47 months for biochemical 
relapse (Joung et al., 2010). Of the 17 PSCA-positive cases, 41.2% relapsed as opposed 
to 23.3% of the PSCA-negative patients. 
A recent study showed that the silencing of PSCA gene with siRNAs arrests the growth 
of cells of a human prostate cancer cell line PC-3M and restricts their invasiveness and 
proliferation (Zhao et al., 2013). This implies a possibility to utilize PSCA as a 
therapeutic modality. 
2.3.7 SPINK1 (serine peptidase inhibitor, Kazal type 1) 
Paju and colleagues first showed that tumor-associated trypsin inhibitor (TATI), the 
protein product of serine peptidase inhibitor Kazal type 1 (SPINK1) gene located in 
chromosome 5 (Horii et al., 1987), is expressed in prostate tissue in both benign and 
malignant regions, and the results were confirmed at mRNA level by RT-PCR (Paju et 
al., 2007). All BPH tissues also stained at least weakly for TATI in 
immunohistochemistry experiments. Studies have indicated a growth factor role for 
SPINK1, and based on murine experiments, it is also suggested to act as a trypsin 
inhibitor and autophagy regulator (Ohmuraya & Yamamura 2011). 
Since the initial prostate-related study, several studies have linked the upregulation of 
TATI with prostate cancer, but reports on SPINK1 at the mRNA transcript level are 
infrequent and mostly limited to urine-based studies. Sabaliauskaite and colleagues 
(2012) examined SPINK1 transcript levels in 158 prostate carcinoma tissues and 21 
noncancerous prostatic tissue samples by qRT-PCR, but did not see any significant up- 







Reports on the usefulness of SPINK1 transcript detection in urine are contradictory. In 
a study by Laxman and colleagues (2008), urine of men with suspected prostate cancer 
was measured for SPINK1 mRNA expression among other markers, and SPINK1 was 
shown to be useful for discriminating cancer patients from biopsy-negative men both 
on its own and as a part of a multiplex setting with PCA3, TMPRSS2-ERG and 
GOLPH2 transcripts. However, in a recent study by Jamaspishvili and colleagues 
(2011), these results were not reproduced, and a model of four best-performing 
markers (AMACR, PCA3, TRPM8 and MSMB) functioned equally well in comparison 
to a full model that included SPINK1. A study by Dimitriadis and colleagues (2013) 
evaluating SPINK1 transcript levels in the urine of 66 men scheduled for prostate 
biopsies also failed to show any benefits of urinary SPINK1 detection. Fourteen cases 
of cancer were subsequently found, but the ratio of SPINK1/KLK3 mRNA levels was 
not significantly different between the cases and controls (Dimitriadis et al., 2013). 
A specific aspect of SPINK1 expression that has generated interest recently, is its 
claimed mutual exclusivity with the TMPRSS2-ERG genomic rearrangement. TATI 
expression, detected by immunohistochemistry, has been found exclusively (Tomlins 
et al., 2008; Bismar et al., 2012) or at least more frequently (Han et al., 2009; Bhalla et 
al., 2013; Grupp et al., 2013; Leinonen et al., 2013) in cancer cases without the 
TMPRSS2-ERG fusion gene. Studies have spanned cohorts consisting of both 
castration-resistant and localized prostate cancers. The mutual exclusivity was shown 
recently even at the level of individual cells by Lippolis and colleagues (2013). 
However, in a study on 186 hormonally-treated prostate cancers, this association was 
absent (Leinonen et al., 2010). On a rare study performed at the mRNA transcript 
level, tissue from 28 cancerous prostates demonstrated outlier pattern in SPINK1 
mRNA expression in cancer types that lacked the ERG rearrangement (Jhavar et al., 
2009). This was a genome-wide expression study performed on microarrays. All in all, 
the possibility of a subgroup of TMPRSS2-ERG negative prostate cancers presenting 
high SPINK1 expression creates an interesting target for research. 
2.3.8 TMPRSS2-ERG fusion gene 
The fusion between TMPRSS2 (transmembrane protease serine 2) and ERG (ETV-
related gene) genes was identified in 2005 to be a recurring event in prostate cancer 
(Tomlins et al., 2005). Other fusion partners for the androgen-regulated, prostate-
specific TMPRSS2, such as ETV1, ETV4, and FLI1, have later been discovered, but 
ERG remains the most prevalent of them (Tomlins et al., 2005; Tomlins et al., 2009; 
Paulo et al., 2012).  
The genes are located on the same chromosome, TMPRSS2 in locus 21q22.2 and ERG 
in 21q22.3. Over 20 different fusion variants have been identified (Tomlins et al., 
2009), and individual tumors have been shown to be able to contain more than one of 
these variants (Furusato et al., 2008). There are different potential fusion breakpoints, 







consensus is that the fusion joins together the promoter region of TMPRSS2 and the 
coding region of the ERG gene. The most common isoform, called TMPRSS2-ERG III 
or TMPRSS2-ERG a (Wang et al., 2006; Furusato et al., 2008), consists of the exon 1 
of TMPRSS2 and the exons of ERG coding region from exon 4 onward. Due to the fact 
that TMPRSS2 is regulated by androgens, the gene fusion can lead to a prostate-
specific overexpression of the transcription factor ERG, possibly in a truncated form. 
Approximately 90% of the prostate cancers with ERG overexpression have presented 
the TMPRSS2-ERG fusion (Tomlins et al., 2005). In addition to the fluorescence in situ 
hybridization (FISH) break-apart assay originally used to detect the gene 
rearrangement, and RT-PCR assays measuring the fusion mRNA transcripts, the 
detection of the ERG protein by immunohistochemistry is one of the possible gene 
fusion identification methods (Tomlins et al., 2005; Park et al., 2010). Studies have 
compared the abilities of the FISH and RT-PCR assays to identify the presence of the 
fusion gene, and concordances higher than 80% between the methods have been 
reported (Tu et al., 2007; Fernandez-Serra et al., 2013). These earlier experiments were 
performed on FFPE tissues in which, conceivably, the RNA quality may have been 
compromised, but Svensson and colleagues, using fresh frozen biopsy tissue, recently 
found a good concordance between the TMPRSS2-ERG FISH assay and a 
transcription-mediated assay for the fusion gene mRNA (Svensson et al., 2014). 
The TMPRSS2-ERG gene fusion has been claimed to be a cancer-specific 
rearrangement, and present in a subset of prostate cancers. In the initial studies using 
FISH and RT-PCR, this rearrangement was found in the prostate tissue of 30–50% of 
localized prostate cancers and in 19–21% of PIN tissues, but in none of the control 
tissues that had been obtained from BPH, prostates with inflammation, or 
histologically benign tissue of cancerous or cancer-free prostates (Cerveira et al., 2006; 
Perner et al., 2007; Attard et al., 2008). The frequency of the fusion gene was found to 
be similar among localized and metastasized cases of prostate cancer. By FISH 
analyses, the rearrangement was seen in 42–49% of localized prostate cancers and in 
30–41% of metastatic cases (Perner et al., 2006; Perner et al., 2007; Gopalan et al., 
2009). Later, the subgroup showing the fusion has been suggested to represent roughly 
half, or 40–70% of all prostate cancers (Tomlins et al., 2009). A higher frequency has 
been observed in Caucasians than in African-American, Indian or Japanese cohorts 
(Magi-Galluzzi et al., 2011; Rawal et al., 2013).  
The initial findings generated a lot of enthusiasm in the research related to TMPRSS2-
ERG. Despite the fact that its functions are still not fully understood, knowledge on the 
causative factors and consequences has increased rather rapidly, and ten years later, the 
annual number of new publications on the subject is still rising exponentially 
(Figure 2). This is conceivable as many aspects of the biology and potential relevance 
of the fusion are still unclear, and the correlation between the fusion gene or its specific 








Figure 2. The number of new TMPRSS2-ERG related publications in PubMed database after 
the publication of the initial study. The number for the current year, 2014, was estimated based 
on the number of reports published during the first quarter of the year. 
The association between the fusion gene in general and poorer survival has sometimes 
been reported (Attard et al., 2008), but that observation has not been evident in all 
studied cohorts (Gopalan et al., 2009). An isoform associated with aggressive cancer 
(TMPRSS2-ERG VI) was identified early, but the data have not been conclusively 
repeated (Wang et al., 2006). Another specific variant called TMPRSS2(exon(0))-ERG 
has been associated with a good cancer prognosis (Hermans et al., 2009). 
It has been suggested that the actual fusion process might be important to the 
prognosis. All studied castration-resistant, metastatic cancers presented fusion through 
deletion instead of translocation, but only 39–60% of the localized cancers were of the 
deletion subtype (Mehra et al., 2008). The aggressive forms have been found to be 
associated with fusion through deletion also in other studies (Han et al., 2009; Perner et 
al., 2006); especially the subtype where the area of fusion through deletion has been 
duplicated is associated with poor survival (Attard et al., 2008; Gopalan et al., 2009). 
The mechanism that introduces the fusion has been examined and androgen has been 
shown to be able to induce the proximity of TMPRSS2 and ERG, thereby facilitating 
the fusion in case of a subsequent double-strand break in DNA. This has been shown in 
both nonmalignant cells and in LNCaP, the prostate cancer cell line derived from a 
lymph nodal metastasis, that does not inherently harbor the fusion gene (Mani et al., 







In addition to tissue-level studies, TMPRSS2-ERG transcript detection has also been 
applied to noninvasive settings. Among the first researchers, Laxman and colleagues 
(2006) detected the fusion mRNA by qRT-PCR in the post-prostatic massage urine of 
42% of the 19 prostate cancer patients. Hessels and colleagues (2007) used 
semiquantitative RT-PCR combined with Southern blotting to find the fusion 
transcripts in a cohort of 108 men. Of the 78 men who were diagnosed with prostate 
cancer at biopsy, 37% were found to have TMPRSS2-ERG mRNA in their urine. This 
mirrors the rate found in the Laxman study as well as the frequency observed in 
prostate tissues. 
The initially claimed high cancer specificity of TMPRSS2-ERG has later been 
questioned in a few studies that have demonstrated TMPRSS2-ERG transcript 
expression in BPH tissue or histologically benign tissue in cancerous prostates. Clark 
and colleagues (2007) first reported finding the fusion mRNA in 8/17 cancer-adjacent 
benign tissues. These data were later repeated by Furusato, Sabaliauskaite, and Robert 
with their colleagues, with 2/45, 4/21, and 5/32 cancer-adjacent benign tissues, 
respectively, showing TMPRSS2-ERG expression (Furusato et al., 2008; Sabaliauskaite 
et al., 2012; Robert et al., 2013). The Robert study also found the fusion transcripts in 
8% of the 48 studied BPH tissues. Occasionally, TMPRSS2-ERG has also been 
detected in urine in the absence of cancer cells at subsequent needle biopsies (Hessels 
et al., 2007; Nguyen et al., 2011; Bories et al., 2013; Leyten et al., 2014). These 
results, combined with the findings of TMPRSS2-ERG in PIN, suggest that the gene 
fusion is an early event in the neoplastic process. The rate of false-negative biopsies 
could also indicate that cancer could be present and has just been missed by the biopsy 
procedures. In fact, in the Ngyuen study, one of the TMPRSS2-ERG positive men with 
TMPRSS2-ERG positive urine was diagnosed with prostate cancer at a repeat biopsy. 
Additionally, in a study where 461 men with high-grade PIN were evaluated for ERG 
expression by immunohistochemistry, it was shown that a higher proportion of ERG-
positive men developed cancer within a follow-up time of three years (Park et al., 
2014). 
2.3.9 TRPM8 (transient receptor potential melastatin 8) 
Ca2+ signaling is known to play a role in the apoptosis, differentiation and proliferation 
of cells, and in cellular functions such as secretion. The entry of calcium is controlled 
by ion channels in the plasma membranes (Flourakis & Prevarskaya 2009). TRPM8 
(transient receptor potential melastatin 8) was identified as a predominantly prostate-
specific gene coding for a protein that has transmembrane domains, and acts as a Ca2+ 
permeable ion channel. The gene is located in chromosome 2q37 (Tsavaler et al., 2001; 
Zhang & Barritt 2004). Of other normal tissues, only testis tissue shows a low level of 
TRPM8 mRNA expression with a trace-amount expression seen in lung, breast, 








TRPM8 expression is related to androgens (Zhang & Barritt 2004; Bidaux et al., 2005; 
Bai et al., 2010), and the differentiation status of the cells. In differentiated cells of the 
prostate epithelium, the TRPM8 channels can be found in plasma membranes or in the 
endoplasmic reticulum, but the plasma membrane-specific expression is lost in poorly 
differentiated cells (Bidaux et al., 2007). However, the prostate-specific function of the 
TRPM8 channel in normal or cancerous conditions is not fully clear (Flourakis & 
Prevarskaya 2009). Somehow the inhibition of the channel expression or the channel 
function slows down the growth of malignant prostate cells, but does not have an effect 
on normal prostate cells (Valero et al., 2012).  
With both in situ hybridization and RT-PCR methods, TRPM8 mRNA has been found 
to be expressed in normal prostate tissue but also, at a higher level, in cancerous 
prostate tissue and in cancerous tissues from other organs (Tsavaler et al., 2001; 
Fuessel et al., 2003; Bai et al., 2010). Using qRT-PCR, it was shown that TRPM8 
transcripts are significantly overexpressed in cancerous lesions compared to matched 
nonmalignant prostate tissue with a 3.7 times higher expression in cancer tissue 
(Schmidt et al., 2006b). However, a subsequent decrease or loss of TRPM8 mRNA 
expression in tissue in more advanced stages of cancer has been demonstrated 
(Henshall et al., 2003; Schmidt et al., 2006b). This seems to suggest that despite an 
increase at the onset of cancer, TRPM8 expression has a protective role, hindering the 
cancer progression to advanced stage. This is supported by the finding that the 
activation of the TRPM8 channels by PSA reduces the motility of PC3 cells (Gkika et 
al., 2010). Hence, the loss of TRPM8 can lead to increased cell migration. 
Measurements of TRPM8 mRNA transcripts in urine have demonstrated higher 
transcript levels in metastatic patients than in patients with localized disease, whereas 
they have failed to discover a significant difference between healthy men and men with 
localized cancer (Bai et al., 2010). In the same study, a similar trend was seen in 
peripheral blood specimens; this is more likely to be caused by a higher prostate cell 
count in these bodily fluids than upregulated TRPM8 expression. In a separate study on 
multiple biomarkers, and similarly to MSMB as described in Chapter 2.3.4, the TRPM8 
transcript level was reported to enhance a multiplex model for the detection of early 
prostate cancer in urine samples (Jamaspishvili et al., 2011). 
2.3.10 Summary on candidate genes 
As discussed in Chapter 2.3, previous works by other researchers have indicated that 
connections exist between prostate cancer and the expression of the 12 candidate 









Table 4. Connections found between the 12 candidate genes and prostate cancer. 
Candidate gene Suggested connection to prostate cancer 
BMP-6 Upregulated in cancer, particularly in metastasized cases. 
FGF-8b Upregulated in cancer. 
KLK2 Highly expressed in prostate; Upregulated in cancer. 
KLK3 Highly expressed in prostate; Constantly expressed or slightly downregulated 
in cancer; Produces PSA that often leaks to circulation in prostatic diseases. 
KLK4 Upregulated in cancer; Correlation with cancer stage. 
KLK15 Upregulated in cancer; Correlation with cancer stage. 
MSMB Highly expressed in prostate; Downregulated in cancer. 
PCA3 Highly upregulated in cancer. 
PSCA Upregulated in cancer and high-grade PIN. 
SPINK1 Upregulated in cancer; Overexpressed predominantly in cancers where 
TMPRSS2-ERG fusion is absent. 
TMPRSS2-ERG Rearrangement found only in men with prostate cancer and more rarely, with 
BPH. 
TRPM8 Upregulated at the onset of cancer, decrease in expression in advanced stages. 








3  AIMS OF THE STUDY 
The main objective of this doctoral work was to evaluate the suitability of 12 candidate 
genes for prostate cancer diagnostics by measuring their expression levels in prostate 
tissue and peripheral blood of men with and without prostate cancer. Novel, highly 
sensitive, and internally standardized qRT-PCR assays were developed for the accurate 
detection of the mRNAs produced by the target genes. 
More specifically, the aims were: 
I  To evaluate the alterations in PCA3 and KLK3 gene expression in the blood of 
 men with localized prostate cancer, metastasized prostate cancer, other 
 prostatic diseases, and healthy individuals by measuring their mRNA levels in 
 circulating cells with novel qRT-PCR assays. 
II  To assess the differences in the mRNA expression of ten biomarker candidates 
of prostate cancer – BMP-6, FGF-8b, KLK2, KLK3, KLK4, KLK15, MSMB, 
PCA3, PSCA and TRPM8 – between cancerous and histologically benign 
tissue of prostate cancer patients with novel qRT-PCR assays. 
III  To study the differences in the mRNA expression levels of TMPRSS2-ERG 
 fusion gene, SPINK1, and PCA3 in prostate tissue of men with and without 
 clinical  prostate cancer with novel qRT-PCR assays. 
IV  To examine, with reference to the location of the carcinoma foci in the 
prostate, the alterations in the expression of PCA3 and TMPRSS2-ERG 
mRNAs as well as that of ERG protein in the prostates of men with prostate 









4 SUMMARY OF MATERIALS AND METHODS 
The detailed descriptions of the materials and methods used in this study are presented 
in the original publications (I–IV). A brief summary along with a few additional details 
is provided here.  
4.1 Clinical samples 
Clinical samples were obtained from participants with their informed consent. The 
cohorts are summarized in Table 5 and described in more detail in Chapters 4.1.1–
4.1.4. The study protocols were approved by the local ethics committees and they were 
in accordance with the Helsinki Declaration of 1975, as revised in 1996. 
Table 5. Summary of the clinical samples used in this doctoral work. 
Collection site Study population Sample matrix Number of 
samples 
Publication  
TUH, Turku, Finland Men with prostate 
cancer 
Blood 67 I 
TUH, Turku, Finland Men with 
nonmalignant prostatic 
diseases 
Blood 8 I 
DBUT, Turku, Finland Healthy male and 
female volunteers 
Blood 16 I  
TUH, Turku, Finland Men with localized 
prostate cancer 
Tissue from RP 
specimens 
174 II, III 
SUH, Malmö, Sweden Men with urinary 
bladder cancer 
Tissue from CP 
specimens 
19 III 
TUH, Turku, Finland Men with localized 
prostate cancer 
Tissue from RP 
specimens 
5 IV 
TUH, Turku University Hospital; DBUT, Department of Biotechnology, University of Turku; SUH, Skåne 
University Hospital; RP, radical prostatectomy; CP, cystoprostatectomy. 
4.1.1 Peripheral blood from prostate cancer patients and healthy 
individuals (I) 
Peripheral blood was obtained from 67 men with prostate cancer, one patient with 
benign prostatic hyperplasia (BPH), and seven patients with prostatic infection from 
Turku University Hospital, Turku, Finland. Blood was also drawn from 16 healthy 
volunteers. From each individual, 2.5 mL of blood were collected into PAXgene™ 
Blood RNA tubes (PreAnalytix) containing the RNA stabilizing solution, mixed by 
inverting the tube and stored at –20 °C. Either before or after storage, the sample was 
 
 




incubated for 24 h at room temperature according to the manufacturer’s instructions 
before further processing. 
4.1.2 Prostate tissue from prostate cancer patients (I, II, III) 
Prostate tissue was collected from 87 men who had undergone radical prostatectomy 
due to clinically localized prostate cancer at Turku University Hospital, Turku, 
Finland. Two small samples were obtained from each fresh prostatectomy specimen 
immediately after surgery, one aimed to sample the cancerous area and the other a 
control site. The tissue area adjacent to samples was later examined microscopically by 
an experienced pathologist for histology and samples were subsequently classified as 
cancerous, PIN, or histologically benign tissue. Of the 174 samples, 88 were classified 
as histologically benign tissue, 86 as cancerous samples, and 12 samples fell into the 
PIN category but were considered as noncancerous samples in further analyses unless 
stated otherwise. Sample tissues were stored in a solution containing 4 mol/L 
guanidine thiocyanate, 25 mmol/L sodium citrate dehydrate, 0.5% (w/v) sodium lauryl 
sarcosinate and 0.7 % (v/v) 2-mercaptoethanol, and they were stored at –80 °C until 
further processing. 
4.1.3 Prostate tissue from bladder cancer patients (III) 
Prostate tissue was collected from 19 men who had undergone cystoprostatectomy due 
to urinary bladder cancer at Skåne University Hospital, Malmö, Sweden. One sample 
was obtained from each cystoprostatectomy specimen and the prostate was further 
sectioned and examined pathologically to inspect the gland for incidental cancer foci. 
Seven glands were classified as tumor-free whereas 12 were deemed to contain 
incidental tumor foci in prostate regions other than the sampled area. Samples were 
stored fresh frozen at –80 °C until further processing. 
4.1.4 Prostate tissue from cross-sections of prostate cancer patients (IV) 
Prostate tissue from single cross-sections of the prostate was collected from five men, 
who had undergone radical prostatectomy due to prostate cancer at the Turku 
University Hospital, Turku, Finland. A slice of approximately 2 mm in thickness was 
cut horizontally from each prostate, and further cut into 5x5x2 mm pieces using a 
Styrofoam plate grid as a template (Figure 3). Hence, 44–62 pieces were obtained from 
each prostatectomy cross-section, depending on the size of the gland. Samples were 
stored in RNA stabilizing solution, RNAlater® (Ambion), at –20 °C until further 
processing. Tissue sections next to the slice from both the superior and inferior side of 
the prostate were examined histologically by a pathologist to determine carcinoma, 
PIN, and histologically benign areas and to match the tissue histology with the 
corresponding samples of the mRNA experiments performed later. Tissue next to the 
sections undergoing the histological examination was fixed in formalin and embedded 
in paraffin to create macro blocks of tissue for immunohistochemistry experiments. 
 
 





Figure 3. The sample collection flowchart of the cross-section study. A horizontal cross-section 
was cut from each studied prostate and further divided into 2x5x5 mm pieces that were used for 
mRNA measurements. (Figure from original manuscript IV.) 
4.2 RNA extraction and reverse transcription (I, II, III, IV) 
Total RNA was extracted from the blood samples using PAXgene Blood RNA kit 
(Preanalytix) according to the manufacturer’s instructions, and a known, fixed amount 
of artificial RNA (Nurmi et al., 2000b) was added to each sample after cell lysis to act 
as an internal standard. During the extraction, samples were treated with RNAse-free 
DNAse I (Qiagen) according to manufacturer’s instructions to degrade and eliminate 
the contaminating genomic DNA. 
Total RNA was extracted from the tissues using RNeasy Mini kit (Qiagen) according 
to the manufacturer’s instructions including the DNAse treatment, and with the 
modification of adding a known, fixed amount of artificial RNA (Nurmi et al., 2000b) 
to each sample after cell lysis. The tissue material stored in guanidine thiocyanate 
solution was first homogenized in the storage solution to include the RNA that had 
potentially dissolved into the storage buffer, after which the lysis buffer was added.  
Extracted total RNA was characterized by gel electrophoresis for RNA degradation 
and the concentration was measured spectrophotometrically, after which RNA was 
reverse transcribed into cDNA using High Capacity cDNA Archive kit (Applied 
Biosystems) according to manufacturer’s instructions and using the random primers 
provided in the kit. The cDNAs were stored at –20 °C. 
4.3 Standards (I, II, III, IV) 
A fixed amount of artificial RNA was used as an internal standard to track the inherent 
loss of RNA throughout the steps of the processing protocol, and target-specific, 
external DNA standards were used in real-time PCR. 
 
 




4.3.1 Internal RNA standard 
A mutated form of wild-type KLK3 (the gene coding for the protein PSA) RNA was 
used throughout the study as the internal standard. Compared to the wild-type KLK3 
sequence, the standard, called mmPSA, contains a deletion and inversion in its 
sequence to make it an unrecognizable target for the KLK3 real-time PCR assay. The 
standard used here had been manufactured earlier at the Department of Biotechnology, 
University of Turku (Nurmi et al., 2000b). A known amount of mmPSA, 106 
molecules, was added to each tissue and blood sample during RNA extraction. The 
amount of mmPSA present in sample cDNAs was measured by a separate mmPSA-
specific real-time PCR assay to obtain a value for the extent of RNA loss during 
sample processing; this was subsequently used for normalizing the target mRNA copy 
numbers. A control for the real-time PCR assay, representing the maximum yield of 
internal standard RNA, was prepared by performing reverse transcription on the same 
amount of internal standard RNA as was added to the samples. 
4.3.2 External DNA standards 
Purified PCR products were used as external DNA standards in each real-time PCR 
assay. For each mRNA target, the corresponding PCR product was produced in an end-
point PCR assay and the DNA was purified from agarose gel. The DNA concentration 
was measured with the fluorescein-based Picogreen reagent kit (Invitrogen), and the 
final product was diluted to different concentrations for use in real-time PCR assays. 
4.4 Real-time PCR (I, II, III, IV) 
The expression of the target genes (BMP-6, FGF-8b, KLK2, KLK3, KLK4, KLK15, 
MSMB, PCA3, PSCA, SPINK1, TMPRSS2-ERG III, TMPRSS2-ERG VI, TRPM8) was 
determined by real-time PCR assays. The assay principle is based on a closed-tube 
concept that utilizes oligonucleotide probes, and it was previously developed at the 
Department of Biotechnology, University of Turku (Nurmi et al., 2002). 
4.4.1 Assay design 
Real-time PCR assays were specifically designed for each gene target and a small 
amplicon size was preferred to minimize the effect of RNA degradation on the results. 
The amplicon location was designed to preferably match the sequence between exon-
intron boundaries in order to favor the amplification of reverse-transcription produced 
cDNA and avoid the amplification of traces of potential contaminating DNA in the 
samples. Previously published primers and probes were utilized for PCA3 (de Kok et 
al., 2002), KLK2 (Ylikoski et al., 2001; Rissanen et al., 2007), KLK3 (Nurmi et al., 
2000a; Nurmi et al., 2002) and TMPRSS2-ERG III assays (Tomlins et al., 2005; 
Cerveira et al., 2006). The oligonucleotides used in the other mRNA assays were 
 
 




designed specifically in this doctoral work. Assay performance was optimized 
individually for each assay by adjusting reaction conditions to maximize sensitivity 
and reproducibility, and to minimize unspecific amplification. 
4.4.2 The principle of real-time detection of amplification products 
The real-time detection principle of PCR amplification products is based on a 
previously published closed-tube concept (Nurmi et al., 2002). Briefly, target-specific 
oligonucleotide probes hybridize to the target DNA sequence of the PCR product 
before the primers anneal (Figure 4).  
 
Figure 4. The principle of the real-time detection of PCR amplification. The accumulation of 
the PCR products was monitored in real-time during the PCR cycling using target-specific 
oligonucleotide probes labeled with lanthanide chelates and complementary probes carrying 
quencher molecules. (Figure from original publication I.)  
At the annealing/extension temperature, DNA polymerase, while synthesizing the new 
DNA strand, encounters the hybridized probe and cleaves it off, simultaneously and 
irreversibly releasing the lanthanide chelate label from the 5’ end of the 
oligonucleotide into the solution. The fluorescence of the intact probes is quenched by 
separate oligonucleotide probes carrying quencher molecules; these are capable of 
specifically hybridizing to intact reporter probes and turning off the fluorescence of 
their lanthanide chelate labels. Hence, fluorescence signal is recorded from released 
lanthanide chelate labels only and it is proportional to the amount of accumulated PCR 








4.4.3 Real-time PCR reagents and conditions 
The sequences of the oligonucleotides used in the real-time PCR assays of this study 
are shown in Table 6. PCR primers, as well as quencher probes containing either QSY-
7® or Dabcyl at the 3’ end as the quencher molecule, were purchased from Thermo. 
Reporter probes were also purchased from Thermo, and they contained a phosphate 
group at the 3’ end and an amino-C6 modification at the 5’ end.  
They were labeled in-house with terbium or europium chelates according to previously 
developed protocols where the lanthanide chelates were attached to the amino group 
(Nurmi et al., 2000a). Briefly, target-specific oligonucleotides were incubated with a 
100-fold molar excess of the lanthanide chelate overnight at +4 °C and subsequently 
purified with size-exclusion gel chromatography (Nick columns, Pharmacia) and high-
performance liquid chromatography using a gradient between 0.05 M triethylamine 
acetate (TEAA) in H2O (pH 6.8) and 0.05 M TEAA in acetonitrile (pH 6.8) as the 
eluting component. Purified oligonucleotides were quantified for DNA concentration 
and fluorescence, tested for quenching properties, and stored at –20 °C. 
In each PCR reaction, 2.5 µL of cDNA or DNA standard were used as template on a 
96-well plate (ABgene Thermo-Fast 96 Robotic Plate white, Thermo Scientific, or 
Hard-Shell PCR plate BLK/WHT, Bio-Rad). In negative control PCR reactions, 2.5 µL 
of DMPC-treated H2O were used instead of DNA template. Total reaction volume was 
25 µL in all assays except for the TMPRSS2-ERG III assay, where it was 10 µL. 
Hotmaster DNA polymerase (Eppendorf) was used in the assays for KLK2, KLK3, 
PSCA, and TRPM8 mRNAs, and AmpliTaq® Gold DNA polymerase (Applied 
Biosystems) was used in all the other assays. Both polymerases contain 3’->5’ 
exonuclease activity that is essential for the reporter probe cleavage. The detailed 
concentrations of the reagents in each assay are shown in Table 7.  
The PCR thermal profile consisted of a denaturation step (15 s at +95 °C) and an 
annealing/extension step (1 min at +64 °C or +62 °C) that were repeated for 45 cycles 
in a PTC-200 thermal cycler (MJ Research). For added specificity, the 
annealing/extension was performed at the higher temperature, +64 °C, for the first ten 
cycles, and in the remaining cycles at +62 °C. Starting at cycle 11 for TMPRSS2-ERG 
III assay and at cycle 17 for all the other assays, the fluorescence signals were 
measured from the reaction wells in a time-resolved manner with a fluorometer 
(Victor, PerkinElmer) after every odd-numbered cycle. Measurement was carried out 
after a 15-second incubation at +35 °C. When AmpliTaq® Gold DNA polymerase was 









Table 6. The oligonucleotides used in the real-time PCR assays of this doctoral work. 




BMP-6    
     5’ primer GCA TCA TCA GCA CAG AGA CTC 
TGA C 
NM001718 1025–1046 
     3’ primer ACG TGG ACT CCA TCC CTT G NM001718 1177–1195 
     reporter probe GGC TGG AAT TTG ACA TCA CGG 
CCT G 
NM001718 1093–1117 
     quencher probe TCA AAT TCC AGC C NM001718 1093–1105 
FGF-8b    
     5’ primer CTG CCT CCA AGC CCA GGT A NM_006119 224–242 
     3’ primer CGG CTG AGC TGA TCC GTC A NM_006119 295–313 
     reporter probe GCT CTG CTC CCT CAC ATG CTG 
TGT 
NM_006119 267–290 
     quencher probe ATG TGA GGG AGC AGA GC NM_006119 274–290 
KLK2    
     5’ primer GAA CCA GAG GAG TTC TTG CG NM005551 522–541 
     3’ primer CCC AGA ATC ACC CCC ACA A NM005551 665–683 
     reporter probe ACA TGT GTG CTA GAG CTT ACT 
CTG AGA AGG 
NM005551 586–615 
     quencher probe AGC TCT AGC ACA CAT GT NM005551 586–602 
KLK3    
     5’ primer TGA ACC AGA GGA GTT CTT GAC X05332 523–543 
     3’ primer CCC AGA ATC ACC CGA GCA G X05332 667–685 
     reporter probe CCT TCT GAG GGT GAA CTT GCG 
C 
X05332 596–617 
     quencher probe AAT CAC CCT CAG AAG G X05332 600–601, 
604–617 
KLK4    
     5’ primer GGC ACT GGT CAT GGA AAA CG NM_004917 138–157 
     3’ primer CAG CCC GAT GGT GTA GGA GTT NM_004917 223–243 
     reporter probe CAG CAC CCA CTG CGG ATG CAC 
CAG 
NM_004917 178–201 








(continued from the previous page) 




KLK15    
     5’ primer CTG CCA AAG CCG CTT C AY373373 186–201 
     3’ primer ATG ACC CGA GAC GTG G AY373373 263–278 
     reporter probe CGC CTG GGA GAG CAC AAC CTG AY373373 211–231 
     quencher probe CTC TCC CAG GCG AY373373 211–223 
mmPSA    
     5’ primer TGA ACC AGA GGA GTT CTT GCA X05332 523–543 
     3’ primer CCC AGA ATC ACC CGA GCG A X05332 667–685 




     quencher probe AAT CAC CCT CAG AAG G X05332 600–601, 
604–617 
MSMB    
     5’ primer CCT GCT TAT CAC AAT GAA TGT 
TC 
NM_002443 20–42 
     3’ primer CAT TCA CTG ACA GAA CAG GTC NM_002443 347–367 
     reporter probe TCC TTC TTC TCC ACC ACG ATA 
TAC TTG C 
NM_002443 310–337 
     quencher probe GTG GAG AAG AAG GA NM_002443 324–337 
PCA3    
     5’ primer GGT GGG AAG GAC CTG ATG ATA 
C 
AF103907 95–116 
     3’ primer GGG CGA GGC TCA TCG AT AF103907 505–521 
     reporter probe AGA AAT GCC CGG CCG CCA TC AF103907 478–497 
     quencher probe CCG GGC ATT TCT AF103907 478–489 
PSCA    
     5’ primer CTG TTG ATG GCA GGC TTG GC NM005672 77–96 
     3’ primer GGC CAA CTG CGC GGA TG NM005672 211–227 
     reporter probe AGC CAG GCA CTG CCC TGC TGT 
G 
NM005672 102–123 
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SPINK1    
     5’ primer GAC CTC TGG ACG CAG AAC NM_003122 96–113 
     3’ primer GTA ACA TTT GGC CTC TCT TCC NM_003122 199–219 
     reporter probe AAG GTA ACA GGC ATC TTT CTT 
CTC AGT G 
NM_003122 124–151 
     quencher probe TGC CTG TTA CCT T NM_003122 124–136 
TMPRSS2-ERG III    
     5’ primer TAG GCG CGA GCT AAG CAG GAG NM_005656.3 4–24 
     3’ primer GTA GGC ACA CTC AAA CAA CGA 
CTG G 
NM_004449.4 338–362 










TMPRSS2-ERG VI    
     5’ primer CGG CAG GTC ATA TTG AAC ATT 
CC 
NM_005656.3 73–95 
     3’ primer GCA CAC TCA AAC AAC GAC TGG NM_004449.4 338–358 
     reporter probe CTT TGA ACT CAG AAG CCT TAT 









TRPM8    
     5’ primer GAG TTG GAT CAA ATG GCT CAA NM_024080 1165–1185 
     3’ primer GGT GCT GAA GGC TTT GTA TAG NM_024080 1274–1294 
     reporter probe ATG GCA TTG CTC ACA ATT TCA 
TCC CCA 
NM_024080 1237–1263 








Table 7. The reagent concentrations in the real-time PCR assays. 
















BMP-6 100 0.2 0.025 2.5 4 170 
FGF-8b 100 0.2 0.025 2.5 17 170 
KLK2 100 0.2 0.016 - 17 170 
KLK3 100 0.2 0.016 - 17 170 
KLK4 100 0.2 0.025 2.5 17 170 
KLK15 100 0.2 0.016 2.5 17 170 
mmPSA 100 0.2 0.025 2.5 17 170 
MSMB 100 0.1 0.025 2.5 17 170 
PCA3 100 0.2 0.025 2.5 17 170 
PSCA 100 0.2 0.016 - 17 170 
SPINK1 100 0.1 0.025 2.5 17 170 
TMPRSS2-ERG 
III 
100 0.2 0.025 1.5 170 1700 
TMPRSS2-ERG 
VI 
500 0.4 0.050 2.5 43 170 
TRPM8 100 0.2 0.016 - 17 170 
 
4.5 Immunohistochemistry (IV) 
The ERG protein expression was determined from the FFPE (formalin-fixed, paraffin-
embedded) macro blocks of tissue in the prostate cross-section study (IV). Sections of 
5 µm in thickness were cut from the blocks with a microtome and stained with a 1:250 
dilution of the rabbit monoclonal ERG antibody (clone EPR3864, Epitomics). 
Detection was carried out with EnVision™+ Dual Link System-HRP (Dako) as the 
secondary antibody, and using DAB+ Chromogen (Dako) for the visualization of the 
stained tissue areas. 
4.6 Data analysis 
4.6.1 Real-time PCR data (I, II, III, IV) 
Signal-to-background ratios were calculated for each reaction and plotted against the 
PCR cycle number. Quantification cycles (Cq) were determined visually for each 
 
 




reaction as the cycle where the fluorescence level started to significantly differ from 
the background level. The differences between the Cqs of the external DNA standard 
reactions and the Cqs of the reactions of the maximum yield of internal standard RNA 
were calculated for each DNA standard concentration separately, and the standard plots 
were constructed by plotting the obtained differences in the Cqs against the ten-based 
logarithm of the target-specific standard concentration. The same difference in the Cqs 
was determined for each unknown sample reaction, and the mRNA copy numbers were 
calculated on the basis of that and normalized to sample size using either volume or 
total RNA amount. After normalization, the blood sample data are presented as mRNA 
copies per mL of blood, and the tissue sample data as mRNA copies per µg of total 
RNA. 
Samples were run as three PCR replicate reactions and, unless stated otherwise, were 
considered to contain the target only when all three reactions produced fluorescence 
signals that differed from the background.  
The limit of detection (LOD) was defined as the lowest concentration of external DNA 
standards that produced a fluorescence signal differing from the background. The limit 
of quantification (LOQ) was defined for the blood samples as the concentration of 
mRNA in blood that consistently produced the above-mentioned level of fluorescence 
(I). 
4.6.2 Immunohistochemistry data (IV) 
The tissue slides stained with the ERG antibody in the immunohistochemistry 
experiments were evaluated for ERG expression by a pathologist. For a comparison of 
the locations of positive staining with the corresponding tissue samples in the mRNA 
experiments of the original manuscript IV, digital images were taken of the tissue 
slides used in the immunohistochemistry experiments, and divided into an equal 
amount of regions similarly to the tissue cross-sections, and each region being marked 
as either containing detectable ERG expression or not. 
4.6.3 Statistical analysis 
Statistical analysis for publications II and III was performed with Stata 10.0 at the 
Department of Epidemiology and Biostatistics of Memorial Sloan-Kettering Cancer 
Center (New York, NY, USA). Univariate logistic regression was used to analyze the 
association between mRNA expression and the studied parameters of the tissue 
samples. 
SPSS 20.0 (IBM) was used to perform the statistical analyses for publication IV, and 
nonparametric tests were used to analyze the associations between histology and 
mRNA expression levels.  
 
 




5 SUMMARY OF RESULTS AND DISCUSSION 
This doctoral work concentrated on evaluating the RNA expression of 12 candidate 
biomarker genes in prostate tissue, but it also assessed the possibility to detect two of 
them in circulating cells in blood. A summary of the results of the original publications 
is presented here. 
5.1 Gene expression in circulating tumor cells in peripheral blood 
(I) 
The current diagnostic routine of prostate cancer ultimately relies on the histological 
analysis of prostate biopsies. The biopsy procedure is an invasive method that may also 
be risky and have adverse effects such as bleeding or infection, and will prove 
inconvenient for monitoring purposes when frequent follow-up sampling is required. 
For clinical diagnostics, less invasive methods such as urine or blood tests would 
therefore be preferred.  
Cells can be shed into blood circulation by the primary tumor in the prostate due to 
cancer-related changes in the organ structure even when the tumor foci are small or the 
volume of the tumor is low (Schmidt et al., 2006a; Ali et al., 2010). These circulating 
tumor cells are thought to be the cause of metastatic forms of cancer if they migrate to 
a distant secondary site, attach and start proliferating. The presence of circulating 
tumor cells has been particularly suggested as a monitoring tool to predict potential 
cancer recurrence. Using varied methods, the tumor cells can be detected in blood 
either on the basis of their cancer-specific or their organ-specific characteristics, such 
as particular nucleic acid content, but the challenge is their low level in blood. The 
high background count of lymphocytes makes it difficult to reliably analyze the tumor-
related cell content of blood, and sensitive analysis techniques, such as RT-PCR, are 
therefore required (Alix-Panabieres & Pantel 2013). 
In this doctoral work, two candidate RNAs, those of PCA3 and KLK3, were evaluated 
for their suitability for the detection of circulating prostate cancer cells in blood. The 
RNA expression of these genes was measured in peripheral blood samples of 67 
prostate cancer patients and 24 noncancer controls with real-time qRT-PCR assays. 
Measurable levels of either of the studied RNAs were only found in patients with 
metastatic prostate cancer. Samples from two out of the nine studied men with 
metastasized prostate cancer contained measurable levels of PCA3 RNA (Figure 5A), 
but PCA3 RNA transcripts were not detected in any of the samples from healthy 
controls (n=16), men with localized prostate cancer (n=58), or men with other prostatic 
diseases (n=8). Quantifiable levels of KLK3 mRNA were found in 4/9 blood samples 
of men with metastatic prostate cancer (Figure 5B).  
 
 





Figure 5. PCA3 and KLK3 mRNA expression in the blood of prostate cancer patients, men with 
other prostatic diseases and healthy individuals. BPH, benign prostatic hyperplasia; PCa, 
prostate cancer. A. PCA3 mRNA expression levels. B. KLK3 mRNA expression levels. Open 
diamonds show samples with only KLK3 mRNA expression, closed diamonds denote samples 
that also contained PCA3 mRNA. (Figure modified from original publication I.) 
 
 




Additionally, one healthy control, one sample from a man with clinically localized 
prostate cancer and two samples from the metastatic group were discovered to contain 
KLK3 mRNA, but at levels lower than the assay LOQ, making them, therefore, 
unquantifiable. The low overall number of PCA3 or KLK3 positive samples in this 
study could be explained by the absence of prostate cells in the samples that were 
mostly obtained from cases of localized cancer. The even lower positivity rate of PCA3 
compared to KLK3 could also be due to a lower expression level of PCA3. This was 
supported by the finding that the median mRNA expression of KLK3 was 28 times 
higher than the PCA3 RNA level in prostate tissue of ten tested radical prostatectomy 
specimens.  
The concentration of circulating tumor cells is usually very low in blood compared to 
the background of millions of blood cells, and the current consensus is that an 
enrichment step is needed to improve the detection sensitivity. Enriching can be 
accomplished by capturing the tumor cells from blood with immunoaffinity techniques, 
using their tumor cell-specific surface molecules as markers, or by using their physical 
properties such as size or electric charge as the factors separating them from peripheral 
blood cells (Alix-Panabieres & Pantel 2013). In this work the resources were not 
available to perform the enrichment, but a strong concordance has been demonstrated 
for the performance of this RT-PCR concept and the FDA-cleared enrichment method, 
CellSearch® (Veridex), to detect circulating prostatic tumor cells in blood (Helo et al., 
2009). Additionally, results similar to those obtained in this work were also obtained in 
another study even after using immunomagnetic enrichment of the circulating tumor 
cells: PCA3 RNA was found only in the blood of men with advanced prostate cancer 
with no PCA3 RNA detected in healthy controls or men with androgen-dependent 
cancer (Jost et al., 2010). Also the observed difference of approximately one 
magnitude between KLK3 and PCA3 RNA levels was in concordance with the results 
of this doctoral work. However, another report using enrichment techniques on blood 
from men with CRPC, found PCA3 RNA in the blood circulation of all 15 study 
subjects, and also low levels in one of the healthy controls (Shaw et al., 2008). Other 
reports on PCA3 RNA in men are rare but some studies have detected it even without 
the enrichment of the cells (Marangoni et al., 2006; Neves et al., 2013). The assays 
performed in this doctoral work did not detect any PCA3 expression in the healthy 
individuals.  
Findings of KLK3 mRNA in peripheral blood have been more frequent than those of 
PCA3 RNA, and several qualitative and quantitative methods have been employed for 
detection. Already in 1994, the detection of KLK3 mRNA in blood of men with 
localized prostate cancer was reported, and it was found with even higher frequency in 
metastatic cases (Katz et al., 1994). As noted also in this doctoral work, the trend is to 
find KLK3 mRNA more frequently in prostate cancer patients with a non-organ-
confined disease (Olsson et al., 1996; Zhang et al., 2008), but as reviewed by 
Kalfazade and others, the data on whether the preoperative levels of KLK3 mRNA in 
blood help in staging the cancer or predicting recurrence are contradictory (Kalfazade 
 
 




et al., 2009). Most of the early data are obtained by qualitative or semiquantitative 
methods, which can account for the discrepancy between different results, and qRT-
PCR is recommended for the most accurate information (Kurek et al., 2003). 
5.2 Gene expression in prostate tissue (II, III, IV) 
While circulating tumor cells provide an interesting, a less invasive possibility for 
prostate cancer detection and monitoring, the research for finding and validating new 
biomarkers starts often at tissue level. The potential cancer-related cells that are shed 
into the blood circulation originate from the primary organ, and therefore the molecular 
examination of prostate tissue is highly important. Furthermore, the application of 
molecular assays on biopsy material could add value to the histological analyses at 
diagnosis. 
Radical prostatectomy is a routine procedure in prostate cancer treatment, and tissues 
from radical prostatectomy specimens are rather readily available for research, 
providing both cancerous and histologically benign samples. Noncancerous tissue is 
more challenging to obtain due to the limited availability of suitable candidates. 
Benign hyperplastic prostate tissue collected at TURP procedures is often used as 
control tissue in studies. In this doctoral work, the gene expression of the candidate 
biomarkers in prostate tissue was examined in radical prostatectomy specimens and in 
cystoprostatectomy specimens from men with urinary bladder cancer. 
Cystoprostatectomy comprises the removal of prostate along with the bladder and a 
subsequent pathological dissection of the prostate for incidental tumors; this is an 
advantage compared to the material obtained from TURP procedures, where only 
tissue shavings are removed and collected, but the remaining organ can still harbor 
unknown malignancies. 
The scientific literature offers a continuous flow of new candidate genes for 
biomarkers of prostate cancer and 12 such genes were selected for this doctoral work: 
BMP-6, FGF-8b, KLK2, KLK3, KLK4, KLK15, MSMB, PCA3, PSCA, SPINK1, 
TMPRSS2-ERG and TRPM8. The selection was made on the basis of their altered 
expression in prostate cancer at protein or RNA level in previously reported studies, 
and the RNA expression of these genes was measured in prostate tissues of 87 men 
with clinical prostate cancer. The expression of KLK3, PCA3, SPINK1, and TMPRSS2-
ERG was also measured in further 19 men with bladder cancer but without clinical 
prostate cancer. To be able to assess the differences in gene expression with regard to 
cancer development, samples were collected from both cancerous and histologically 
benign areas of the radical prostatectomy specimens of prostate cancer patients. The 
measured RNA levels were compared to sample characteristics, such as sample 
histology, Gleason grade, and the pathological stage of the cancer, to find out which 
genes performed best at stratifying between cancerous and benign tissue or between 
different stages of cancer. 
 
 




KLK2, KLK3, KLK4 and MSMB mRNAs were found to be expressed generally at the 
highest levels, followed by TRPM8, BMP-6, PCA3, PSCA, and SPINK1 RNAs (Figure 
6) (II, III). The expression levels for KLK15, TMPRSS2-ERG and FGF-8b mRNAs 
were the lowest among the studied genes and in fact, FGF-8b mRNA was undetectable 
in 70% of the radical prostatectomy samples. Of the two studied mRNA variants of 
TMPRSS2-ERG fusion gene, isoform III was detected in 48% and isoform VI in 47% 
of the samples of the radical prostatectomy cohort. 
 
Figure 6. Expression levels of 13 target genes in 174 prostate tissues from prostate cancer 
patients. Levels are shown only for those samples where expression was quantifiable. The 
10/25/50/75/90th percentiles are marked in the figure. 
5.2.1 PCA3 (II, III, IV) 
PCA3 gene was first found to be associated with prostate cancer in 1999 (Bussemakers 
et al., 1999). Its overexpression in cancerous tissue has been reported several times and 
depending on the study, the magnitude has ranged from 10 up to 100-fold 
overexpression (Bussemakers et al., 1999; de Kok et al., 2002; Hessels et al., 2003; 
Robert et al., 2013). In this doctoral work a statistically significant, 5.8 times higher 
expression was seen in the carcinoma areas of 86 radical prostatectomy samples when 
compared to the median expression in the 88 samples from the histologically benign 
areas of the same cohort (p<0.05) (Figure 7) (II). This was at the lower end of the 
reported ranges, but a more pronounced, over 600-fold increase in PCA3 RNA 
 
 




expression was found when the cancerous tissues were compared to the 19 
cystoprostatectomy tissues of men without clinical cancer (p<0.0001) (Figure 7) (III). 
The resulting, over 100-fold difference in the medians between PCA3 RNA levels in 
the histologically benign prostate tissue of cancerous prostates and prostates without 
clinical cancer suggests that the carcinoma-surrounding, but histologically benign, 
areas of the cancerous prostates already show molecular changes, i.e. increased PCA3 
expression.  
 
Figure 7. Expression of PCA3 RNA in the histologically benign tissue of prostates without 
clinical prostate cancer, prostates with malignant tumor, and cancerous tissue. Levels are shown 
only for those samples where expression was quantifiable. The 10/25/50/75/90th percentiles are 
marked in the figure and the open circles denote the outlier values. HBP, histologically benign 
prostate. 
The molecular level alterations in gene expression can be explained by the field 
cancerization theory. First described in 1953 (Slaughter et al., 1953), it suggests that a 
larger area of the tissue than just the area covering the tumor foci is originally changed 
in terms of molecular content, and that a certain area within that zone can then further 
develop into a neoplastic lesion after experiencing the additional necessary changes in 
cell functions. The altered expression of PCA3 in benign areas of cancerous prostates 
has previously been studied by in situ hybridization (Popa et al., 2007), and a finding 
that benign glands in closer proximity to the carcinoma show PCA3 expression more 
frequently than similar glands more distant from the malignant tumor, was claimed to 
be caused by the cancer field effect. Approximately 30% of the benign glands were 
 
 




demonstrated to be positive for PCA3 RNA. More recently, Warrick and colleagues 
(2014) found PCA3 RNA expression in benign glands of nine cases out of the 41 
studied prostatectomy specimens. Yet, neither of these studies found the phenomenon 
of field cancerization regarding PCA3 to be as widespread as the results of this doctoral 
work would suggest. The question of the histologically benign samples being 
contaminated by cancer cells or their nucleic acids could therefore be raised here, but 
several precautions were taken to avoid crosscontamination in this doctoral work. 
Sterile, disposable laboratory equipment was always used and the handling of clean 
PCR reagents was carried out in a designated hood that was physically separate from 
the workspaces dedicated to sample processing, RNA extraction, and PCR template 
work. The workspaces were cleaned with ethanol and ultraviolet radiation after every 
use to deplete and destroy any leftover nucleic acids. The opening of reagent tubes 
post-PCR amplification that was required by the gel electrophoresis experiments, could 
have naturally posed a threat of crosscontamination by PCR products, and therefore it 
was also performed in a different laboratory room. Negative control reactions with 
sterile water as template were always run in parallel to every real-time PCR assay to 
ensure that the reagents and disposables were free of contaminating DNA.  
The origins of the benign tissues used for controls in previous studies are not always 
specified, but Hessels and colleagues (2003) used a study set-up similar to the one used 
in this doctoral work, comparing PCA3 RNA levels between carcinoma tissues and 
benign areas in cancerous prostates. They reported a 10–60-fold overexpression which 
is still of a higher magnitude than was found in this doctoral work even though there is 
an equal possibility that both cohorts could have been affected by the cancer field 
effect. Robert and colleagues (2013) have, however, shown increased PCA3 RNA 
levels also in the benign regions of cancerous prostates when they were compared to 
BPH tissue. The PCA3 expression was found to be three times lower in the BPH tissue. 
Of the cohort of 87 prostate cancer patients, 46 men provided one cancerous and one 
histologically benign sample with quantifiable PCA3 expression, enabling the 
examination of the RNA level variation between matched samples. The median 
overexpression observed in the cancerous areas compared to the matched benign area 
was 2.9-fold (II). The hypothesis of altered expression in the histologically benign 
regions was further studied by obtaining cross-sections from five prostates with 
carcinoma, systematically dividing the tissue slice into smaller areas each covering 5x5 
mm of tissue, and measuring the PCA3 expression in all of those areas separately (IV). 
The adjacent superior and inferior tissue was examined histologically by a pathologist, 
providing information about the matched morphology of the tissue, and on the basis of 
these data, each sample area was assigned as a carcinoma area, a PIN area, or a 
histologically benign area. The carcinoma areas were found to contain 3.1–3.6 times 
higher levels of PCA3 RNA than the benign areas (p<0.001), depending on whether the 
benign sample was located right next to a carcinoma sample – which admittedly, for 
technical reasons, could therefore contain occasional cancer cells – or further away 
 
 




from the malignant tumor (Figure 8). This value supports the finding of 2.9-fold 
difference (II) that was obtained using just two matched samples per prostate. 
 
Figure 8. PCA3 expression in the benign, malignant and PIN lesion areas of cross-sections of 
five cancerous prostates. The 10/25/50/75/90th percentiles are marked in the figure and the open 
circles denote the outlier values. Open diamonds denote the negative samples. PIN, prostatic 
epithelial neoplasia. (Figure modified from original manuscript IV.) 
The levels of PCA3 were found to be positively associated with advanced cancer stage 
with higher PCA3 levels in the tissues of men with stage T3 or T4 cancer (p=0.015), 
but no association was seen between the Gleason grade of the tissue and the PCA3 
RNA level. This suggests that PCA3 alone cannot provide a reliable cancer staging. 
The fact that an increase in PCA3 RNA expression is seen already in the histologically 
benign areas of a cancerous prostate when compared to a clinically noncancerous 
prostate, could indicate a possibility to identify cancerous prostates on the basis of 
samples obtained from their histologically benign areas. There was an overlap in RNA 
levels between the two groups of histologically benign samples but, if validated, this 
finding suggests that this molecular assay could potentially provide further useful 
information in addition to the histological analysis of the tissue for example for men 
with negative prostate biopsies. The current prostate biopsy sampling protocol cannot, 
despite ultrasound guidance, guarantee that the biopsy needle will reach the tumor 
focus and, therefore, the assay would be a valuable addition to assessing the risk of 
 
 




cancer in the prostate, if relevant molecular information could be retrieved also from 
those biopsy cores that missed the carcinoma.  
5.2.2 TMPRSS2-ERG (III, IV) 
TMPRSS2-ERG fusion gene was discovered in 2005 and it is thus far the most common 
genetic rearrangement seen in epithelial cancers (Tomlins et al., 2005). Depending on 
the study cohort, the gene fusion can be detected in 40–70% of prostate cancers, but its 
significance or that of its mRNA variants in terms of patient outcome is still being 
debated. In this doctoral work, TMPRSS2-ERG mRNAs were found to be expressed in 
the prostates of 72% of the 87 men with prostate cancer, which is in accordance with 
the previous reports. Two of the over 20 reported mRNA isoforms (Tomlins et al., 
2009) produced by the different variants of the fusion gene were selected for the study: 
isoform III is the most commonly found variant (Tomlins et al., 2005) and isoform VI 
was associated with an aggressive form of prostate cancer in one of the early studies 
(Wang et al., 2006). 
Both mRNA variants, TMPRSS2-ERG III and TMPRSS2-ERG VI, were found more 
frequently in the cancerous tissues of men with prostate cancer than in the 
histologically benign areas of the same patient cohort (p=0.022 and 0.026, 
respectively) (III). Of the 86 cancerous tissue samples, 49 (57%) showed expression of 
isoform III and 47 (55%) contained mRNA variant VI (Table 8). In the histologically 
benign tissues, TMPRSS2-ERG III was found in 35/88 (40%) samples and TMPRSS2-
ERG VI in 34/88 (39%) samples. However, it has to be noted that among the samples 
where the fusion gene mRNA levels were quantifiable, cancerous tissue did not show 
significantly higher or lower TMPRSS2-ERG mRNA levels in comparison to the 
benign cohort. 
In a notable contrast to the men with prostate cancer, only two in the group of 19 men 
without any indication of clinical prostate cancer showed a detectable expression of 
TMPRSS2-ERG in their prostate tissue (Table 8). Furthermore, both of those two 
prostates were later on found to contain incidental microscopic tumor foci elsewhere in 
the prostate. This finding gave rise to the systematic study of five prostate cross-
sections (IV), where it was shown that even though the entire cross-section of a 
prostate obtained from a TMPRSS2-ERG fusion-positive cancer case was not 
expressing the fusion gene mRNA, the mRNA was, in addition to being expressed in 
the carcinoma regions and areas immediately adjacent to them, also detectable in five 
of the samples from the histologically benign tissue areas. However, these data can be 
considered as preliminary at best, due to the limited sample size. ERG protein 
expression was examined in the immediately adjacent cross-sections of tissue from the 
same prostates by immunohistochemistry, and positive ERG staining was limited to 
one prostate and to those carcinoma areas, where also TMPRSS2-ERG mRNAs were 
detected. However, despite the positive mRNA expression, additional areas where 
 
 




ERG protein expression could not be detected were found, suggesting that the qRT-
PCR assay has a higher sensitivity compared to the immunohistochemistry method.  
Table 8. TMPRSS2-ERG III and VI mRNA expression detected in the prostate tissue of men 
with or without clinical prostate cancer. (Table modified from original publication III.) 
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0 (0%) 1 (5%) 1 (5%) 17 (89%) 19 
RP, radical prostatectomy; HBP, histologically benign prostate; CP, cystoprostatectomy. 
Previous studies identifying TMPRSS2-ERG fusion gene areas with the same ERG-
specific antibody that was used in this doctoral work had similar levels of correlations 
between the nucleic acid tests and immunohistochemistry. A study by van Leenders 
and colleagues (2011) showed that all samples that were found to be positive for 
TMPRSS2-ERG mRNA by qRT-PCR, also contained ERG protein, whereas Park and 
colleagues (2010) found three cases out of 131 cancers where TMPRSS2-ERG fusion 
was detected by FISH without corresponding ERG protein expression. Nineteen men 
with prostate cancer provided two cancerous radical prostatectomy samples for the 
study, and three (16%) of them showed the expression of TMPRSS2-ERG mRNAs in 
only one of their cancerous samples, suggesting that not all carcinoma foci within a 
single prostate contain the fusion gene, and indicating the multiclonal nature of the 
disease (III). It has also been shown that within a single prostate the malignant tumor 
can be TMPRSS2-ERG fusion-negative, and the benign area can present the fusion 
gene (Clark et al., 2007). We found this to be rare, but possible: in six (13%) of the 48 
cancer cases that provided one cancerous and one histologically benign tissue sample 
for this study, TMPRSS2-ERG mRNA expression was detected in only the 
histologically benign tissue and not in the matched cancerous sample. In 33/48 (69%) 
cases the TMPRSS2-ERG expression was concordant regarding the presence or absence 
of the fusion mRNA. 
 
 




Furthermore, 24 (27%) and 39 (45%) of the 88 histologically benign and 86 cancerous 
radical prostatectomy samples, respectively, showed expression of both isoforms in the 
same sample (Figure 9). A particular tumor focus can contain more than one isoform of 
the gene fusion (Furusato et al., 2008) and they can presumably be a result of 
differential mRNA splicing of a single DNA-level gene fusion (Clark et al., 2007).  
 
Figure 9. TMPRSS2-ERG III and VI mRNA expression in 86 cancerous and 88 histologically 
benign prostate tissue samples of radical prostatectomy specimens. Closed diamonds denote the 
cancerous samples and open diamonds represent samples from histologically benign areas. 
(Figure from original publication III.) 
The claimed cancer specificity of the TMPRSS2-ERG fusion gene originally referred to 
carcinoma areas (Tomlins et al., 2005), but later, there were reports stating that cancer-
adjacent tissue, PIN lesions, and hyperplastic areas sometimes manifested TMPRSS2-
ERG fusion (Clark et al., 2007; Furusato et al., 2008; Robert et al., 2013). Still, so far, 
neither this doctoral work nor other studies have been able to find the fusion gene in 
the tissue samples of men without any prostatic diseases. A urine test for TMPRSS2-
ERG has been positive in two men with negative prostate biopsies, but they could have 
had undetected cancers (Hessels et al., 2007).  
 
 




As described in section 5.2.1 discussing PCA3 mRNA, the expression of TMPRSS2-
ERG mRNAs in the histologically noncancerous areas can be due to molecular 
precursor changes in the tissue, and could provide the potential to use the phenomenon 
for identifying prostates currently harboring malignant foci, or running the risk of 
developing a carcinoma in the future. Furthermore, if a certain mRNA variant could be 
associated with an aggressive form of the disease, an early discovery could enable an 
early intervention with necessary measures. 
5.2.3 PSCA (III) 
PSCA mRNA was found to be underexpressed in the cancerous tissues of men with 
prostate cancer. The median expression level of PSCA was 2.9 times lower in them 
than in the histologically benign tissue of the same cohort (p=0.046). PSCA mRNA 
levels were not associated with the Gleason grade of the tissue or the advanced cancer 
stage. The overlap of the ranges of PSCA mRNA expression levels between cancerous 
and histologically benign areas and the barely statistically significant difference 
between the medians in the group indicate only a moderate trend of PSCA 
underexpression in cancer cells. The earliest reports on PSCA claimed increased 
expression in cancer detected by in situ hybridization (Zhigang & Wenlv 2004), but 
later, no significant difference was seen in mRNA levels between cancerous tissues 
and matched histologically benign samples when measuring them with qPCR (Schmidt 
et al., 2006b). A protein level study examined differences between incidental cancers 
found in cystoprostatectomies and cancerous areas of radical prostatectomies, and 
despite the lower number of PSCA-positive cells in the incidentally found cancers, the 
difference was not statistically significant (Mazzucchelli et al., 2009). In this doctoral 
work, the cystoprostatectomy specimens were not examined for PSCA expression due 
to a limited availability of material. 
5.2.4 SPINK1 (III) 
SPINK1 gene has been claimed to be overexpressed in prostate cancer and the 
expression has often been found to be limited to prostate cancer cases that do not 
present the TMPRSS2-ERG gene fusion (Tomlins et al., 2008). In this doctoral work, 
SPINK1 mRNA levels were indeed 2.9 times higher in the cancerous than in the 
histologically benign areas of cancerous prostates (p=0.047) (Figure 10). The lowest 
SPINK1 mRNA levels were detected in the tissues of men without clinical prostate 
cancer – 10 times lower than in cancerous tissues (p<0.001). This led also to a 
statistically significant, 3.4-fold difference (p=0.010) in the median levels of SPINK1 
mRNA expression in histologically benign tissues depending on whether the tissue 
originated in a cancerous prostate or in a prostate without clinical cancer.  
 
 





Figure 10. SPINK1 mRNA expression in histologically benign tissues from men without and 
with clinical prostate cancer, and cancerous prostate tissue. For the group without cancer, the 
horizontal line denotes the median value, and the open circles denote SPINK1 mRNA values in 
individual samples. For the other two groups, the 10/25/50/75/90th percentiles are marked in the 
figure and the open circles denote the outlier values. HBP, histologically benign prostate. 
(Figure modified from original publication III.) 
In general, reports on quantifying SPINK1 mRNA levels in prostate tissue are rare, as 
most of the previous data on prostate-related SPINK1 expression are from 
immunohistochemistry or in situ hybridization experiments, or urine sample cohorts. 
Sabaliauskaite and colleagues (2012) determined SPINK1 mRNA levels in a set-up 
similar to the cohort of this doctoral work, comparing cancerous and noncancerous 
tissues of 179 PCa patients, but did not find a significant difference between the 
groups. The levels in that study were normalized to a reference gene, which introduces 
a potential source of discrepancy between that data and the levels measured in this 
doctoral work, where a normalizing procedure towards an artificial, internal RNA 
control was used. However, it must be noticed that SPINK1 mRNA expression was 
found in noncancerous areas also in the Sabaliauskaite study. In addition, Laxman and 
colleagues (2008) measured SPINK1 mRNA levels in urine samples, and reported an 
increase in men with prostate cancer, but also saw a detectable SPINK1 mRNA 
expression in men with negative biopsies. 
 
 




In this work, SPINK1 expression was neither found to be associated with the Gleason 
grade of the prostate tissue nor an advanced pathological stage of the cancer. Follow-
up times were not long enough to enable a proper analysis of prognosis here, but higher 
SPINK1 levels have been suggested to lead to poorer survival (Leinonen et al., 2010).  
SPINK1 mRNA expression and the mere presence of TMPRSS2-ERG fusion gene were 
not found to be correlated here, but in those men who had the fusion gene, the levels of 
SPINK1 and TMPRSS2-ERG mRNA were statistically significantly associated 
(p=0.001–0.041, depending on the mRNA variant of TMPRSS2-ERG). A study where 
all SPINK1 positive cancers were TMPRSS2-ERG negative (Tomlins et al., 2008), used 
immunohistochemistry to detect TATI, the protein coded by SPINK1, and FISH to 
determine the presence of the fusion gene, as opposed to the qRT-PCR assays used in 
this work. Compared to the protein experiments, the highly sensitive qRT-PCR method 
could therefore detect lower levels of SPINK1 expression, and conceivably there could 
also be differences between the transcription and translation levels of the gene. 
Nevertheless, another study also using FISH and immunohistochemistry for 
TMPRSS2-ERG and SPINK1 level determinations in tissues of a hormonally-treated 
prostate cancer patient cohort did not find a mutual exclusivity between SPINK1 and 
the TMPRSS2-ERG fusion either (Leinonen et al., 2010). Instead, Leinonen and 
colleagues found an equal percentage (11% or 12%) of the fusion-negative and fusion-
positive cases to contain the protein level expression of SPINK1. In the above-
mentioned study of mRNA-level quantification in prostate tissue by Sabaliauskaite and 
colleagues (2012), an increase in SPINK1 levels was seen in the TMPRSS2-ERG 
fusion-negative cases, but the expression was detectable in fusion-positive patients as 
well. Different criteria for categorizing samples as SPINK1-positive could also play a 
role in the contradictory reports via a varying interpretation of the 
immunohistochemistry staining data. The grading of staining intensities and the level 
of staining required for a positive observation are often independently decided by each 
research group.  
5.2.5 KLKs 2, 3, 4, and 15 (II, III, IV) 
The expression levels of KLK3, the gene coding for the PSA protein, and KLK2 were 
among the highest target gene levels seen in the prostate tissue (Figure 6). However, no 
statistically significant differences were found between the tissues originating from a 
cancerous or histologically benign area of a prostate for either of these two or the 
kallikrein-related peptidase genes 4 or 15. Both KLK2 and KLK4 mRNAs are claimed 
to be overexpressed in prostate tissue in cancerous areas compared to benign 
hyperplastic tissue or normal glands (Herrala et al., 2001; Xi 2004; Neves et al., 2008; 
Avgeris et al., 2011), but in this work no such overexpression was observed. 
KLK3 mRNA levels were measured mainly for control purposes. KLK3 expression was 
also measured in all of the samples covering the entire prostate cross-sections of the 
study described in original manuscript IV, but in that study, no significant differences 
 
 




were found in KLK3 mRNA levels that would have corresponded with the tissue 
histology. However, histologically benign tissue from men without clinical prostate 
cancer showed slightly lower levels of KLK3 mRNA than tissues from cancerous 
prostates (1.9-fold difference in medians, p=0.032). This is in contrast to previous 
reports on KLK3 mRNA levels being reduced in cancer compared to benign prostate 
tissue (Herrala et al., 2001; Meng et al., 2002). Nevertheless, as the only studied 
human kallikrein gene, KLK3 was associated with the Gleason grade of the sample and 
the KLK3 mRNA levels were, in fact, lower in tissues with Gleason grades 4 and 5 
when compared to grades 2 and 3 (p=0.018). 
KLK15 was the only human kallikrein gene in the study that was associated with 
advanced pathological stage (II). Tissues of men with cancer of the pathological stage 
3 and 4 had statistically significantly higher levels of KLK15 mRNA (p=0.032), and 
this finding was concordant with previous studies (Rabien et al., 2010; Mavridis et al., 
2013). However, those studies reported also an increase in KLK15 levels in cancerous 
tissue when compared to matched histologically benign glands or benign hyperplastic 
prostate tissue. An earlier study had examined the differential expression of both the 
classical mRNA variant of KLK15 and the three alternatively spliced mRNA variants 
(Mavridis et al., 2010), and only the classical variant was shown to be overexpressed in 
cancer. That is the form later associated with the pathological stage (Mavridis et al., 
2013). In this doctoral work, no distinction was made between the variants due to the 
fact that the information on their potential independent significance was not available 
at the time of the assay design. Therefore, the amplicon region of the KLK15 assay 
extending from the junction of exons 2 and 3 downstream into exon 3, was designed to 
comprise a fragment of the sequence that is present in all reported isoforms of KLK15 
mRNA (Kurlender et al., 2005). Rabien and colleagues do not state explicitly which 
variant they analyzed, but on the basis of the amplicon sequence, it can be deduced that 
their assay also covered all variants equally (Rabien et al., 2010). 
5.2.6 BMP-6, FGF-8b, MSMB, TRPM8 (II) 
MSMB has been claimed to be in the top three of highly expressed genes in prostate 
cells (Lilja & Abrahamsson 1988), with lower mRNA levels in malignant tissue than in 
normal cells (Vanaja et al., 2003). It was one the most highly expressed target genes of 
this study, too (Figure 6), but its mRNA levels in the histologically benign areas and 
cancerous areas of prostate were here found to be within the same range, with no 
statistically significant differences between the groups. No association has been found 
for MSMB mRNA levels and clinical stage or Gleason grade (Tsurusaki et al., 1998; 
Sakai et al., 1999), which is mirrored in the results obtained in this doctoral work. 
Similarly to MSMB, no statistically significant over- or underexpression was seen in 
the cancerous tissues for BMP-6, FGF-8b or TRPM8 mRNAs, which is in contrast to 
earlier reports. In the few reports on BMP-6 mRNA levels in prostate tissue, the gene 
was claimed to be overexpressed in cancer (Harris et al., 1994; Barnes et al., 1995) and 
particularly in metastatic cases (Hamdy et al., 1997). Unfortunately in this doctoral 
 
 




work there were not any specimens available for metastasis-specific analyses. Earlier 
reports on the overexpression of FGF-8b in cancer are contradictory, and some have 
also claimed an association with Gleason grade, while others did not find any (Dorkin 
et al., 1999, Wang et al., 1999). FGF-8b levels were among the lowest of the studied 
genes here, supporting the previous reports on low levels of FGF-8 gene products in 
cells (Ghosh et al., 1996). TRPM8 mRNA levels have also been reported to be 
overexpressed in cancer but with a subsequent decrease in advanced stages (Henshall 
et al., 2003; Schmidt et al., 2006b). However, these results were not reproduced in this 
study.  
The modest discriminatory power seen here suggests that BMP-6, FGF-8b, MSMB and 
TRPM8 are of low importance for the stratification of cancerous and noncancerous 
prostate tissues. However, for the most abundant prostate-specific genes, the 
applicability in cancer diagnostics could reside in their use as markers of prostatic 
origin in the detection of cells in urine or blood, which calls for highly expressed genes 
to ensure maximum sensitivity. In fact, both TRPM8 and MSMB have been shown to 
be useful for the detection of prostate cells in both blood and urine of men with 
metastasized prostate cancer (Bai et al., 2010; Jamaspishvili et al., 2011), which is 
supported by the fact that their expression levels were among the highest observed in 









Currently the prominent opinion is that a single biomarker will not be able to solve the 
problems in prostate cancer diagnostics alone. Instead, a multiplex approach combining 
the measurements of several target molecules is believed to be a more fruitful focus of 
research efforts. The aim of this doctoral work was to evaluate the usefulness of 12 
candidate genes for prostate cancer diagnostics.  
The main conclusions based on the original publications are: 
I PCA3 mRNA could only be detected in the blood of men with metastasized 
prostate cancer, but not in healthy controls, or men with localized prostate 
cancer. Similarly, quantifiable levels of KLK3 mRNA were only seen in 
metastatic cases. The qRT-PCR assay developed in this work for detecting 
PCA3 mRNA provides absolute mRNA levels without reference gene 
determination. 
II Cancerous prostate tissue overexpressed PCA3 mRNA and underexpressed 
PSCA mRNA when it was compared to histologically benign regions in 
prostates. The observed 5.8-fold overexpression of PCA3 was not as notable as 
previously reported. Higher KLK15 mRNA levels in prostate tissue were 
associated with advanced pathological stage of the cancer. The expression of 
the other seven candidate biomarkers, BMP-6, FGF-8b, KLKs 2, 3, 4, MSMB, 
or TRPM8, was not significantly different in cancer tissues and, therefore, 
these genes do not provide discrimination between cancerous and 
noncancerous samples. However, the expression levels of MSMB, KLK2, 
KLK3, and KLK4 were high, and the mRNA transcripts of these genes could 
potentially be used for a cancer-related detection of prostatic cells in other 
body fluids such as urine or blood. 
III The mRNAs of prostate cancer-specific fusion gene TMPRSS2-ERG were 
detected in 72% of the prostate cancer cases, and more frequently in cancerous 
tissue than in benign samples. However, the two mRNA isoforms of the fusion 
gene were found not only in carcinoma areas, but also in histologically benign 
prostate tissue of men with prostate cancer, while not in prostates of men 
without clinical prostate cancer. This could be utilized in assessing the risk of 
undetected prostatic malignancies even on the basis of histologically negative 
prostate biopsies. SPINK1 mRNA was overexpressed in prostate cancer and its 
lowest tissue levels were found in men without clinical prostate cancer. For 
both PCA3 and SPINK1, the mRNA levels were higher in histologically benign 







IV Altered expression of TMPRSS2-ERG and PCA3 can sometimes be found in 
 cancerous prostates also in regions that are outside the carcinoma foci. The 
 qRT-PCR assay for TMPRSS2-ERG fusion gene mRNAs found more 
 positive areas than the immunohistochemistry experiments for the 
 corresponding ERG protein, and it can therefore be suggested to be a more 
 sensitive method for detecting the fusion. The sample size of the study was 
 limited to cross-sections of five prostates, so further validation is needed for 
 these observations. 
Combining the determination of several different nucleic acid levels into a single-
reaction RT-PCR test would require careful design and the optimization of the 
oligonucleotides, other reagents, and reaction conditions to ensure the specific and 
efficient quantification of all targets. A perhaps more feasible alternative for a 
multiplex approach would be to measure the analyte levels separately, and 
subsequently use statistical models to combine the data into an informative measure. 
The road from finding a potential combination of biomarkers to launching a 
commercial test for clinical use is long, and requires validation with multiple test 
panels at several distinct laboratories, and resources for the funding and workforce for 
this kind of clinical validation were beyond the scope of this doctoral work. Instead, 
basic groundwork was laid here, and the most promising biomarkers out of the 12 
studied candidates were identified. Of the 12, PCA3 and TMPRSS2-ERG were the 
markers with the best discriminatory power for diagnostic purposes, but potential for 
prognostic use of any of the studied genes is difficult to assess due to the lack of 
adequate follow-up times for the studied patients. KLK15 mRNA levels did however 
show association with advanced stage. Elsewhere a PCA3 RNA-based urine test has 
already been developed, and this PROGENSA® PCA3 test is being offered to 
clinicians (Groskopf et al., 2006), but evidence on its merits on truly improving health 
outcomes is still insufficient (Bradley et al., 2013). There are also efforts currently 
underway to combine the data on TMPRSS2-ERG status with the PCA3 measurements 
for improved detection of prostate cancer. In addition to these urine tests, other new, 
noninvasive tests showing improvements in the field of prostate cancer detection 
include the 4Kscore™ Test (Vickers et al., 2008; Vickers et al., 2010) and the Prostate 
Health Index (phi) (Jansen et al., 2010), both combining the protein level 
measurements of several different prostate-specific kallikreins in serum. Novel marker 
classes include noncoding RNAs – both long noncoding RNAs (lncRNAs) and shorter 
RNAs such as microRNAs – but these markers are still at the research stage. 
The data obtained in this doctoral work predominantly support the previous findings in 
medical literature in regard to the biomarkers’ cancer specificity and stratification 
potential and, importantly, this work provides further details on the absolute mRNA 
levels of the target genes. It is rare in previous works as most of the reported gene 







The molecular-level alterations regarding TMPRSS2-ERG, PCA3, and SPINK1 
mRNAs seen in the histologically benign tissue of men with prostate cancer, but not 
found in the prostates of men without clinical prostate cancer, can be postulated to be 
caused by the cancer field effect. This phenomenon and the molecular nucleic acid 
tests developed in this doctoral work could be utilized for revealing the potentially 
increased risk of prostate cancer in men who have received negative histological 
biopsy results. If aberrant molecular levels were detected in their histologically benign 
tissue biopsies, it could be an indication of a current undetected malignancy in the 
prostate, or a suggestion of being predisposed to one in the future. In this doctoral work 
the samples were obtained from prostatectomy specimens, and applying the assays to 
prostate biopsies could be an interesting future step for validating this hypothesis. In 
fact, there are already both technical and clinical reports on successful mRNA content 
determinations in biopsy material (Fukabori et al., 2006; Schneider et al., 2008; Zhao 
et al., 2011). In addition to assessing the presence of carcinoma, the molecular assays 
could potentially define a cancer to be of a specific molecular subtype, and this could 
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